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Abstract 
Cervical carcinoma is one of the most frequently diagnosed malignancies in women in 
many countries in sub-Saharan Africa, including South Africa. In sub-Saharan Africa, 
among women without HIV the age-standardised cervical cancer incidence rate is greater 
than 40 per 100 000. However, women infected with both the human-immunodeficiency 
virus (HIV) and the human papilloma virus (HPV) have a higher risk of developing 
cervical carcinoma than women infected with HPV alone. 
Published studies of the ideal staging methods, treatment algorithms, and outcomes for 
women with comorbid locally advanced cervical carcinoma and HIV are scarce. The aim 
of this body of work is to fill some of these gaps. 
We conducted four cohort studies of patients with locally advanced cervical carcinoma 
with or without HIV, recording demographic data, staging information and treatment 
delivered. Additional information gathered for individual studies included treatment 
response and survival outcomes. We evaluated the statistical significance of differences 
between HIV-positive and negative patients. Logistic regression models were utilised to 
evaluate risk for toxicity, treatment response, and survival outcomes. 
In the first of three retrospective cohort studies, among 383 patients, early response to 
chemoradiation was found to be related to advanced stage [OR 2.39, 95% CI 1.45-3.96] 
and completion of brachytherapy [OR 3.14; 95% CI 1.24-7.94] but not HIV status. In the 
second retrospective study, among 213 patients undergoing radical radiotherapy, acute 
Grade 3 / 4 toxicity was associated with receiving chemotherapy [OR4.41; 95%CI 1.76- 
11.1; p 0.023] and having HIV [OR 2.16; 95% CI0.98-4.8; p 0.05]. In a prospective study 
of 492 patients, OS at 5 years was 49.5% (95%CI; 44.6% - 54.4%) among HIV-negative 
patients but only 35.9% (95% CI; 23.9% - 48.0%) among HIV-positive patients (p=0.002). 
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In our Cox models, factors affecting outcome were HIV infection, stage IIIB disease, 
hydronephrosis, and delivery of concurrent chemotherapy. In the fourth cohort study, 
among 273 patients with locally advanced cervical carcinoma who underwent a 
radiotherapy planning PET-CT scan, overall 235 (84.5%) were upstaged. Upstaging was 
not associated with HIV status (HIV-negative 83.9% vs HIV-positive 87.2%; p=0.47). 
Following the PET-CT scan, among the 263 patients who attended for radiotherapy 
treatment, intent changed for 124 patients (46.3%): 53.6% of HIV-positive patients and 
42.9% of HIV-negative patients (p=0.11). 
This body of work demonstrated that in HIV-positive patients, integration of PET-CT into 
staging algorithms for cervical carcinoma is a viable option. During treatment HIV-positive 
patients experienced increased toxicity, but most were able to complete treatment, and 
their 5-year overall survival was nearly 40%. Among women with locally advanced 
cervical cancer, those with HIV infection should be treated with the best standard of care. 
Future research should focus on factors that improve outcomes for these women. 
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Abstrak 
 
Servikale karsinoom is een van die mees gediagnoseerde kwaadaardige gewasse in 
vroue in baie lande in sub-Sahara Afrika, insluitende Suid-Afrika. Die voorkoms van 
servikale kanker is meer as 40 per 100 000 (ouderdom-gestandaardiseerde koers) in 
sub- Sahara Afrika, selfs onder vroue sonder menslike immuniteitsgebrek virus (MIV). 
Vroue met beide MIV en menslike papilloom virus (MPV) infeksies het 'n hoër risiko vir 
die ontwikkeling van servikale karsinoom as vroue wat slegs MPV infeksie het. 
 
Daar is 'n tekort aan gepubliseerde werk oor die ideale stadiërings ondersoeke, 
behandeling algoritmes en uitkomste vir vroue met lokaal gevorderde servikale 
karsinoom en MIV infeksie. Verder dit is onduidelik wat die impak van MIV-positiwiteit 
mag hê op hierdie parameters. Die doel van hierdie navorsing is om sommige van 
hierdie vrae te antwoord. 
Pasiënte, met of sonder MIV en lokaal gevorderde servikale karsinoom is in vier kohort 
studies bestudeer. In al die studies is inligting versamel oor demografie, stadiëring en die 
behandeling ontvang. Bykomende inligting vir individuele studies het respons op 
behandeling en oorlewing-uitkomste ingesluit. Die statistiese betekenisvolheid van 
verskille tussen MIV-positiewe en negatiewe pasiënte is bereken. Logistiese regressie 
modelle is gebruik om die risiko vir newe-effekte, behandelingsuitkoms en oorlewing te 
evalueer. 
In die eerste van die drie terugskouende kohort studies op 383 pasiënte, is bevind dat 
vroeë reaksie op chemo- bestraling betekenisvol verband hou met gevorderde stadium 
van karsinoom [KV 2.39, 95% VI 1.45- 3.96] en voltooiing van bragiterapie [KV 3.14; 95% 
VI 1.24-7.94] maar nie met MIV status nie. In die tweede terugskouende studie, wat 213 
pasiënte 
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ingesluit het wat radikale radioterapie ondergaan het, was akute graad 3 / 4 toksisiteit 
betekenisvol geassosieer met byvoeging van chemoterapie [KV4.41; 95% VI 1.76-11.1; p 
0.023] en MIV positiwiteit [KV 2.16; 95% VI 0.98-4.8; p 0.05]. Vyf jaar algehele oorlewing 
is in 'n prospektiewe studie van 492 pasiënte geëvalueer. Die algehele oorlewing van 
MIV-negatiewe pasiënte was 49.5% (95% VI 44.6% – 54.4%) teen 5 jaar. Die algehele 
oorlewing van MIV-positiewe pasiënte was aansienlik laer, 35.9% (95% VI 23.9% – 
48.0%) teen 5 jaar (p = 0.002). In die Cox modelle was die faktore wat uitkoms beïnvloed 
het, MIV-infeksie, stadium IIIB siekte, die teenwoordigheid van hidronefrose en 
toediening van gelyktydige chemoterapie. In die vierde kohort studie van 273 pasiënte 
met lokaal gevorderde servikale karsinoom, het pasiënte vir radioterapie beplanning 'n 
Pet-RT (rekenaar tomografie) skandering ontvang. In totaal is 235 pasiënte (84.5%) se 
stadiëring verhoog weens die bykomende inligting verkry van Pet-RT skandering. 
Verhoging in stadium het nie verband gehou met MIV-status nie (MIV-negatiewe 83.9% 
teenoor MIV- positiewe 87.2%; p = 0.47). Van die 263 pasiënte wat wel radioterapie 
behandeling ontvang het, is die plan verander vir 124 pasiënte as gevolg van die Pet-RT 
skandering (46.3%), 53.6% van MIV-positiewe pasiënte en 42.9% van MIV-negatiewe 
pasiënte (p = 0.11). 
Hierdie navorsing het getoon dat integrasie van Pet-RT in stadiëring algoritmes vir 
servikale karsinoom 'n redelike opsie is vir MIV-positiewe pasiënte. Verder is aangetoon 
MIV-positiewe pasiënte meer newe-effekte ervaar tydens behandeling, maar in staat is 
om behandeling in die meerderheid van gevalle te voltooi met 'n 5-jaar algehele 
oorlewing van bykans 40%. In vroue met lokaal gevorderde servikale kanker moet 
diegene met MIV-infeksie met die beste standaard van sorg behandel word. 
Toekomstige navorsing moet fokus op faktore wat uitkomste verbeter vir hierdie vroue. 
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1. Chapter 1 - Introduction 
 
1.1 Background 
 
Cervical carcinoma is one of the most frequently diagnosed malignancies in women in 
many countries of sub-Saharan Africa, including South Africa1. In 2018 in South Africa, 
nearly 12 000 women were diagnosed with invasive cervical cancer (ICC), and 5000 
succumbed to it2. Among women in the general population of sub-Saharan Africa, the 
age-standardised cervical cancer incidence rate is greater than 40 per 100 0002. In 
addition, cervical cancer has been considered an AIDS-defining cancer as women 
infected with both the human papilloma virus (HPV), which causes most cervical cancer, 
and the human-immunodeficiency virus (HIV) have a higher risk of developing cervical 
carcinoma than women infected with HPV alone. 
 
 
In high-income countries (HICs), the HPV vaccine has been relatively well received; its 
availability is likely to reduce already low cervical cancer incidence rates over time. 
However, in sub-Saharan Africa, due to the high prevalence of high risk HPV subtypes 
and of HIV, incidence rates are higher and the lack of healthcare funding has been a 
barrier to implementation of population vaccination programmes3. Even if all eligible (pre- 
sexual debut) young girls in sub-Saharan Africa were vaccinated tomorrow, cervical 
cancer incidence would remain high for at least the next decade. Meanwhile, we need to 
study and try to meet the care needs of women with cervical carcinoma with or without 
comorbid HIV, in our resource-limited setting. 
 
 
Where available, a chest X-ray or abdominal ultrasound may aid clinical staging to 
establish the extent of disease. In HICs, magnetic resonance imaging (MRI) and positron 
emission tomography–computed tomography (PET-CT) scanning are widely available to 
facilitate accurate staging; PET-CT in particular appears to be effective in detecting 
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involved lymph nodes and small volume metastatic disease, enabling clinicians to make 
the best use of oncological interventions4. PET-CT is now increasingly available in low- 
and middle-income countries (LMICs), including South Africa. A cohort study in this 
institution showed that more than 35% of patients’ treatment plans were amended after 
PET-CT, either by conversion to palliative regimens or by the addition of extended field 
irradiation for involved para-aortic nodes5. In HIV-infected patients, PET-CT imaging may 
reveal additional fludeoxyglucose F-18 (FDG)-avid pathology, including reactive 
lymphadenopathy, or co-existent infectious disease, such as tuberculosis; these 
abnormal findings are difficult to interpret6. Prior to the commencement of this study, no 
further data were available regarding the utility of PET-CT in HIV-positive women with 
cervical carcinoma. 
 
 
Once a patient with cervical carcinoma has been confirmed as suitable for curative 
treatment, the standard of care includes radical radiotherapy, brachytherapy and 
concurrent chemotherapy. International standards have been set for treatment planning 
and dose fractionation7,8. However, little is known about the efficacy and safety of these 
treatment algorithms for HIV-positive patients. For patients with both advanced cervical 
carcinoma and HIV, anti-retroviral toxicity and immunodeficiency complicate the 
administration of chemoradiation, which would otherwise be the treatment of choice. 
Published studies from LMICs describe small subsets of patients treated with low energy 
cobalt-60 machines using large open fields9,10,11. These studies report that HIV-positive 
patients have higher risks than uninfected patients of skin and gastrointestinal toxicity as 
well as more frequent withdrawal from treatment or subsequent inferior doses. Reviews 
of the management of HIV-positive cervical carcinoma patients in European and 
American populations have not drawn on retrospective or prospective data to compare 
their outcomes to those of HIV-negative patients; in the absence of such data, they have 
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generally concluded that HIV-infected patients should receive the same treatment as 
other patients12,13. 
The results of a randomised trial of chemoradiation vs radiation alone in HIV-positive 
cervical carcinoma patients in South Africa unfortunately remain unpublished. Prior to the 
commencement of this body of research, data on the efficacy and safety of 
chemoradiation for patients with HIV were lacking, and data on the survival outcomes of 
HIV-infected cervical carcinoma patients were limited. Two small cohort studies from 
India and Kenya did not include survival data due to loss to follow-up9,10. Few studies 
reported on outcomes of cervical carcinoma patients in sub-Saharan Africa treated with 
internationally accepted protocols, and most of those studies involved patients who were 
treated on Cobalt-60 low energy machines. Whether, given treatment with advanced 
chemoradiation techniques on high energy linear accelerators (LINAC), patients from our 
local population have comparable outcomes to participants in international studies in 
HICs has been unknown. 
 
 
Although continuous antiretroviral therapy (cART) is prolonging the life expectancy of 
women with HIV, it is not reducing their risk of developing cervical cancer. This research 
attempts to determine the ideal diagnostic pathway and management of the growing 
numbers of HIV-positive women with cervical carcinoma. 
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1.2 Problem Statement 
 
The ideal staging techniques and treatment regimens for HIV-positive cervical carcinoma 
patients needs to be identified to ensure optimal outcomes in this vulnerable and growing 
cohort of patients. 
 
 
1.3 Central Research Theme and Objectives 
 
The central research theme is the impact of HIV status on staging and on clinical 
outcomes following curative chemoradiation in women with locally advanced cervical 
carcinoma from the Western Cape, South Africa. 
 
 
Acute response and toxicity of chemoradiation: 
 
Study 1: 
 
Patients treated for cervical carcinoma with primary radiotherapy with radical intent from 
July 2007 through December 2010, to compare those who are HIV-infected with those who 
are uninfected, regarding: 
Objective 1: Clinical response to treatment 
Objective 2: Completion of treatment 
Study 2: 
Patients treated for cervical carcinoma with primary radiotherapy with radical intent from 
November 2009 through December 2011, to compare those who are HIV-infected with 
those who are uninfected, regarding: 
Objective 1: Acute treatment toxicities 
 
 
Overall survival: 
 
Study 3: 
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Patients who received primary radiotherapy for cervical carcinoma from July 2007 
through December 2011, to compare those who are HIV-infected with those who are 
uninfected, regarding: 
Objective 1: 5-year overall survival (OS). 
 
 
PET-CT as a staging tool: 
 
Study 4: 
 
Patients who underwent PET-CT imaging for cervical carcinoma from January 2015 
through December 2018, to compare those who are HIV-infected with those who are 
uninfected, regarding: 
Objective 1: Change in clinical stage 
 
Objective 2: Additional radiological-pathological findings 
Objective 3: Subsequent change in treatment decision 
 
 
1.4 Research Methodology 
 
The research consists of four studies. 
Study 1: 
Place of research: Tygerberg Hospital, Radiation Oncology Division 
 
Study design: Cohort study 
 
Selection of participants: 461 consecutive cervical carcinoma patients treated with 
primary radiotherapy with radical intent from July 2007 through December 2010. Primary 
radiotherapy includes all patients who received the equivalent of 45 Gray (Gy) external 
beam radiation, a minimum of 18 Gy high-dose-rate brachytherapy and concurrent 
weekly cisplatin chemotherapy where renal function was sufficient (glomerular filtration 
rate > 50ml/min). HIV patients included were immunocompetent with a CD4 count >150. 
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Viral load was untested in this cohort. All patients were prescribed anti-retroviral therapy 
(ART) prior to cervical cancer treatment. 
Exclusion criteria: Patients who were treated only with palliative intent or who previously 
received surgery for cervical carcinoma 
Methodology: Retrospective patient record analysis 
 
Data analysis: The statistical significance of differences in demographic factors, clinical 
parameters, and toxicity between HIV-positive and negative patients was evaluated by 
means of t-tests for continuous variables and chi-squared tests for categorical variables. 
Multivariable logistic regression models were developed to evaluate the association of 
HIV status with adverse outcomes controlling for confounding variables. Data were 
analysed using SPSS (version 18.0; SPSS, Inc., Chicago, Ill). 
 
 
Study 2: 
 
Place of research: Tygerberg Hospital, Radiation Oncology Division 
 
Study design: Cohort study 
 
Selection of participants: 213 consecutive cervical carcinoma patients treated with 
primary radiotherapy with radical intent from November 2009 through December 2011 
with completed toxicity data. Treatment protocol as per Study 1. 
Exclusion criteria: Patients who were treated only with palliative intent or who previously 
received surgery for cervical carcinoma 
Methodology: Retrospective patient record analysis 
 
Statistical analysis: The statistical significance of differences in demographic factors, 
clinical parameters, and toxicity between HIV-positive and negative patients was 
evaluated by means of t-tests for continuous variables and chi-squared tests for 
categorical variables. Multivariable logistic regression models were developed to analyse 
the association of HIV status with risk of developing a grade 3-4 toxicity, controlling for 
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confounding variables. Data were analysed using SPSS (version 21.0; SPSS, Inc, 
Chicago, IL). 
 
 
Study 3: 
 
Place of research: Tygerberg Hospital, Radiation Oncology Division 
 
Study design: Cohort study 
 
Selection of participants: 492 consecutive patients treated for cervical carcinoma with 
primary radiotherapy with radical intent from July 2007 through December 2011. 
Treatment protocol as per Study 1. Active cohort on clinical follow-up. 
 
Exclusion criteria: Patients who were treated only with palliative intent or who previously 
received surgery for cervical carcinoma 
Methodology: 
 
Patient record analysis of active cohort on clinical follow-up. Record demographic and 
disease characteristics. Define treatment parameters. Document overall survival at 5 
years; the starting point is defined as first day of treatment. 
Survival data were acquired from patient records; patients lost to follow-up were tracked 
and traced by means of national person linkage database. 
Data analysis: statistical significance of differences in demographic factors, clinical 
parameters, and toxicity between HIV-positive and -negative patients was evaluated by 
means of t-tests for continuous variables and chi-squared tests for categorical variables. 
The Kaplan-Meier method was used to determine OS and to compare OS of HIV-positive 
and -negative patients. Cox proportional hazards regression models were developed to 
analyse the associations of HIV status with mortality, controlling for confounding 
variables. 
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Study 4: 
 
Place of research: Tygerberg Hospital, Radiation Oncology Division and Nuclear 
Medicine Division 
Study design: Cohort study 
 
Selection of participants: 
 
 Retrospective/Prospective: 278 consecutive HIV-positive and -negative patients 
diagnosed with locally advanced cervical carcinoma who underwent a staging 
PET-CT scan from January 2015 to end December 2018 (all patients referred in 
this time period by the principal investigator). 
 Exclusion criteria: Scan not performed. Small cell and neuroendocrine carcinomas. 
 
Retrospective methodology: 
 
Original data were extracted from patients’ folders 
 
Reports and images were retrieved from the Nuclear Medicine Hermes database. 
Prospective methodology: Patients were identified and consented in the combined 
gynaecology oncology clinic and referred as per routine clinical practice. Patients found to 
have equivocal or ill-defined lesions on the PET-CT were referred for the appropriate 
investigations, including biopsy, to determine the nature of the lesion if technically 
possible. 
PET-CT protocol – all patients with inoperable cervical carcinoma who were fit for primary 
radiotherapy. HIV-positive patients who are immunocompetent with a CD4>150. All HIV- 
positive patients were included irrespective of ARV therapy; viral load was measured. All 
patients diagnosed with HIV were informed and referred routinely to infectious diseases. 
PET-CT was performed as part of routine staging. PET-CT imaging was performed on an 
outpatient basis. The imaging protocol included a whole-body low dose CT, acquisition of 
PET images and a contrast-enhanced pelvic planning scan. 
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Data capture and analysis (retrospective and prospective): Descriptive statistics for 
demographic and staging factors. Determination of the percentage of HIV-infected and - 
uninfected patients upstaged and management changed, by the PET-CT findings relative 
to conventional imaging. Determination of the percentage of equivocal or unrelated 
clinical findings. Statistical significance of differences in demographic factors, clinical 
parameters, and imaging findings between HIV-positive and -negative patients was 
evaluated by means of t-tests for continuous variables and chi-squared tests for 
categorical variables. 
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Completion of and Early Response to
Chemoradiation Among Human
Immunodeficiency Virus (HIV)-Positive and
HIV-Negative Patients With Locally
Advanced Cervical Carcinoma in South Africa
HannahM. Simonds, MB, ChB, MRCP, FRCR1; Jason D. Wright, MD2,3; Naomi du Toit, MB, ChB, MMed Rad Onc, FC Rad Onc1;
Alfred I. Neugut, MD, PhD3,4,5; and Judith S. Jacobson, DrPH, MBA3,4
BACKGROUND: Very few published studies have dealt with the management of locally advanced cervix carcinoma
among human immunodeficiency virus (HIV)-positive patients. The objective of this study was to compare the clinical
characteristics, radiation and chemotherapy treatments, and outcomes in a cohort of HIV-positive and HIV-negative
women with cervical cancer. METHODS: The authors reviewed the charts of 59 HIV-positive patients and 324 HIV-
negative patients who had stage IB1 to IIIB cervical carcinoma and who received radiation therapy. Demographic and
clinical characteristics were compared at the time of diagnosis; and radiation doses, chemotherapy cycles, and
responses were compared at the time of brachytherapy and at 6-week follow-up. Logistic regression models of
response to treatment were developed. RESULTS: Forty-nine HIV-positive patients (88.1%) but only 213 HIV-negative
patients (65.7%) presented with stage IIIB disease (P ¼ .009). Forty-seven HIV-positive patients (79.7%) and 291 HIV-
negative patients (89.8%) completed the equivalent dose of 68 Grays (Gy) external- beam radiation and high-dose-
rate brachytherapy. (P ¼ .03). Of the 333 patients who commenced concurrent chemotherapy, 26 HIV-positive
patients (53.1%) and 212 HIV-negative patients (74.6%) completed 4 weekly cycles of platinum-based treatment.
Follow-up was censured at 6 weeks. In models that included age, disease stage, HIV status, and treatment, a poor
response at 6 weeks was associated only with stage IIIB disease (odds ratio, 2.39; 95% confidence interval, 1.45-3.96)
and receiving an equivalent radiation dose in 2-Gy fractions of <68 Gy (OR, 3.14; 95% CI, 1.24-7.94). CONCLUSIONS:
HIV-positive patients fared worse than HIV-negative patients because of later presentation and a decreased likeli-
hood of completing treatment. The current findings emphasize the importance of completing irradiation therapy. Fur-
ther studies will address the association of these variables with survival. Cancer 2012;118:2971-9. VC 2011 American
Cancer Society.
KEYWORDS: cervical cancer, human immunodeficiency virus-positive, acquired immunodeficiency syndrome-defining
malignancy, radiation, chemoradiation.
INTRODUCTION
Cervical cancer is the second most common cancer in women worldwide and the most common malignancy in
young women in sub-Saharan Africa. In South Africa, women have a 4% lifetime risk of developing the disease.1 One in 6
women of reproductive age in the Western Cape in South Africa is living with human immunodeficiency virus (HIV).2
HIV-positive patients have a greater persistence of the human papillomavirus (HPV), a greater likelihood of developing
DOI: 10.1002/cncr.26639, Received: August 18, 2011; Revised: September 27, 2011; Accepted: September 27, 2011, Published online November 9, 2011 in
Wiley Online Library (wileyonlinelibrary.com)
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high-grade cervical intraepithelial neoplasia, and ulti-
mately a more rapid progression to invasive cervical carci-
noma than women without HIV.3 Highly effective
antiretroviral therapy (HAART) prolongs survival among
women with HIV but does not appear to prevent them
from developing cervical carcinoma; therefore, the
increasing availability of HAART, paradoxically, is likely
to lead to a rise in the incidence of cervical carcinoma.4
Most women with cervical carcinoma in South
Africa present at an advanced stage, precluding the use of
surgery. In 1999, several studies reported that chemora-
diation was superior to radiation alone (the prior standard
of care for women with locally advanced cervical carci-
noma).5-8 A meta-analysis confirmed that the combina-
tion of chemotherapy and radiation therapy was
associated with improved survival for patients with stage
IB2 through IVA cervical cancer.9 Chemoradiation is
now the standard of care, where resource constraints
allow, in South Africa.
However, to our knowledge, no published studies
have focused on the management of HIV-positive patients
who receive chemoradiation for locally advanced cervical
carcinoma. The randomized trials of chemoradiation
reported to date have excluded women with HIV.
Randomized studies currently under way are intended to
address this question. The potential risks of treating HIV-
positive patients with chemoradiation include the addi-
tional risk of infectious morbidity because of immunosup-
pression and drug interactions between HAART and
chemotherapy, including gastrointestinal (GIT) toxicities
and severe skin reactions.
Although data regarding the tolerance of chemora-
diation are lacking for HIV-positive women with cervical
cancer, chemotherapy has now been incorporated into
their treatment. The objective of our current study was to
compare the clinical characteristics, treatments, and out-
comes of HIV-positive and HIV-negative women with
advanced cervical cancer.
MATERIALS AND METHODS
Tygerberg Hospital is a state-funded public hospital in
the Western Cape of South Africa. It provides state oncol-
ogy services to patients from the remote and rural areas of
the province, urban Cape Town, and the suburban area
close to the hospital. Most patients who attend the hospi-
tal have little education, limited incomes, difficulties
accessing care, and comorbidities. The hospital’s oncology
resources for patients with cervical carcinoma are compa-
rable to those of many tertiary care facilities in Europe
and the United States; they include a full Surgical Gyne-
cologic Oncology Unit, access to chemotherapy, and
modern radiation machines with computed tomography
planning and conformal techniques. Since 2007, HAART
has been widely available in the province, and HIV-posi-
tive patients have access to medication and expertise from
the Infectious Diseases Department.
Patient Records
We performed a retrospective study of all women diag-
nosed with invasive cervical cancer between June 2007
and December 2010. Patients included in the study were
those who were diagnosed with histologically confirmed
cervical cancer (International Federation of Gynecology
and Obstetrics [FIGO] stage IB1 to IIIB) and were treated
with curative intent. Patients with early stage disease who
underwent primary surgery were excluded. Approval for
the study was obtained from the Stellenbosch University
ethics committee.
Patients were stratified into 2 cohorts based on HIV
status: HIV-positive and HIV-negative. Clinical and de-
mographic characteristics were extracted from institu-
tional databases. Among HIV-positive patients, prior
receipt of HAART and CD4 cell counts at the start of
treatment were documented. Disease characteristics
included tumor histology, evidence of hydronephrosis,
lymph node involvement (detected by abdominal ultra-
sound or computed tomography studies), disease stage,
and chemoradiation treatment regimen. Treatment varia-
bles included external-beam radiation therapy (EBRT)
dose and fractionation, the number of chemotherapy
cycles, high-dose-rate brachytherapy (HDR) or external-
beam boost dose and fractionation, and overall treatment
time for those who completed prescribed EBRT and
HDR radiation. The total dose of EBRT and HDR radia-
tion received was calculated by using equations for the
equivalent dose in 2-gray (Gy) fractions (EQD2).
10 Rea-
sons for incomplete radiation and/or chemotherapy were
noted when available. Response data were collected at
time of examination under anesthetic (EUA) for brachy-
therapy planning and on clinical examination at 6-week
follow-up in the clinic.
Treatment
The standard treatment protocol at our institution for
patients with locally advanced stage IB2 to IIIB cervical
carcinoma is 46 to 50 Gy in 23 to 25 fractions of EBRT
delivered to the pelvis with concurrent weekly cisplatin
Original Article
2972 Cancer June 1, 2012
Stellenbosch University https://scholar.sun.ac.za
chemotherapy at a dose of 40 mg/m2 for 4 to 6 cycles and
HDR brachytherapy at 20 to 26 Gy in 4 to 5 fractions
starting in week 5 of EBRT.11 The cervix, uterus, parame-
trium, and pelvic lymph nodes up to and including the
common iliacs are delineated on a planning computed to-
mography scan following the guidelines of Taylor et al.12
The para-aortic lymph nodes (PAN) are delineated up to
the renal hilum if the common iliacs or lower PANs are
involved on imaging. This volume is then conformally
planned on the XiO Radiation Treatment Planning Sys-
tem (Computerized Medical Systems, Inc., Maryland
Heights, Mo). The department protocol is EBRT at 2 Gy
per fraction 5 days a week or, alternatively, at 1.8 Gy per
fraction if the patient has a history of abdominal surgery,
is HIV-positive, or has a PAN field. The PAN field
receives 45 Gy, and the pelvic field receives 50.4 Gy.
Patients who have a poor performance status or very
advanced local disease with bilateral hydronephrosis or re-
nal compromise are prescribed 40.05 Gy in 15 fractions at
2.67 Gy per fraction. Treatment is delivered on an 18-
megavolt linear accelerator with multileaf shielding capa-
bilities. During or after the fifth week of EBRT, each
patient is EUA, and her response is categorized as either
complete or partial. A smit sleeve is then placed in the cer-
vical os, and HDR brachytherapy is planned with a stand-
ard plan, straight source to a total dose of 20 to 26 Gy in 4
to 5 fractions.13 The dose is delivered on a Varian Gam-
maMed machine (Varian Medical Systems, Palo Alto,
Calif). Overall treatment time recommended is 55 days or
less as per the American Brachytherapy Society.11
Chemotherapy is prescribed based on an evaluation
of renal function before treatment. The creatinine clear-
ance/glomerular filtration rate (cGFR) is calculated using
the Cockroft-Gault formula or, when available, an ethyl-
ene diamine tetracetic acid (EDTA)-GFR. If the cGFR or
the EDTA-GFR is60mL/minute, then weekly cisplatin
40 mg/m2 for a minimum of 4 cycles is prescribed; if the
rate is 50 to 60 mL/minute, then the dose is reduced by
25% per cycle; and, if the rate is <50 mL/minute, then
cisplatin is not given. If the GFR is 30 to 50 mL/minute,
then carboplatin is given weekly by calculating a dose
based on the area under the curve equals 2 as an alterna-
tive. The regimen consists of prechemotherapy antiemet-
ics, cisplatin diluted in 250 mL normal saline given over
15 minutes, followed by 1000 mL of normal saline over 2
hours, and 20 mg of oral furosemide. In 2009, an addi-
tional 1000 mL prehydration was added to the regimen.
Chemotherapy is delayed if the neutrophil count falls
below 1000/lL if the platelet count falls below 75,000/
lL, or if the patient develops grade 3 GIT toxicity. Chem-
otherapy is discontinued if the cGFR falls below 50mL/
minute or decreases by>50%, if the neutrophil or platelet
count does not recover, or if the patient develops persis-
tent grade 3 GIT toxicity. Patients on hypofractionated
radiation schedules and patients who have serious medical
comorbidities (eg, active tuberculosis) do not receive
chemotherapy.
At the time of diagnosis, patients who have never
been tested for HIV or who have not been tested recently
are referred for testing and counseling. HIV-positive
patients are referred expeditiously for infectious disease
consultation so that they can begin prophylaxis with cotri-
moxazole, and those not already receiving it can com-
mence antiretroviral therapy. Before April 2010, the
standard HAART protocol included stavudine, lamivu-
dine, and efavirenz. Thereafter, tenofovir was substituted
for stavudine at the discretion of the infectious disease
specialist.
HIV-positive patients receive the same treatment for
their cervical cancer as HIV-negative patients, but the
dose per fraction is reduced to 1.8 Gy; and, if the CD4
count is <200 cells/lL, then chemotherapy is omitted.
Patients whose CD4 count is <150 cells/lL may not tol-
erate a long course of radiation; some are treated on a
shortened regimen dependent on performance status.
Statistics
The outcome variables were total dose of EBRT (45 Gy
vs <45 Gy), total dose of HDR (18 Gy vs <18 Gy),
total radiation dose expressed as EQD2 (68 Gy vs <68
Gy; equivalent to 45 Gy in 25 fractions EBRT and 18 Gy
in 3 fractions HDR), total overall treatment time (55
days vs >55 days), the number of cycles of chemotherapy
(4 cycles vs <4 cycles), and clinical response (complete
vs partial) at EUA during or after the fifth week of chemo-
radiation and 6 weeks post-treatment. We compared the
demographic and clinical characteristics of HIV-positive
and HIV-negative patients using t tests for normally dis-
tributed continuous variables and chi-square tests for cate-
gorical variables. Then, we developed multivariable
logistic regression models to analyze the risk of adverse
outcomes, controlling for HIV status, age, disease stage,
and completion of treatment. Results are expressed as
odds ratios (ORs) with 95% confidence intervals (CIs).
All tests were 2-sided, and P values< .05 were considered
statistically significant. We used the SPSS Statistics soft-
ware program (version 18.0; SPSS, Inc., Chicago, Ill).
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RESULTS
Patient Characteristics
In total, 461 patients with stage IB1 to IIIB cervical carci-
noma who met inclusion criteria were identified. Twenty-
four patients were lost to follow-up or declined treatment.
An additional 41 patients (9.7%) received palliative
EBRT alone at doses ranging from 8 Gy to 40.05 Gy
because of either poor performance status or comorbid-
ities. These patients also were excluded from the analysis.
In all, 383 patients initiated curative-intent treat-
ment and were included in the analysis (Fig. 1). These
included 59 HIV-positive patients (15.4%), 19 (32.2%)
of whom who were receiving HAART at the time of their
initial evaluation. The median CD4 count of the HIV-
positive patients was 354 cells/lL (range, 33-1249 cells/
lL), and 88.1% of all HIV-positive patients had a CD4
count >200 cells/lL. The HIV-positive patients were
younger than the HIV-negative patients (median age, 41
years vs 50 years; P< .001).
In total, 49 HIV-positive patients (88.1%) but only
213 of 324 HIV-negative patients (65.7%) presented with
stage IIIB disease (P¼ .009). HIV status was not associated
with histologic subtype (>90% of both HIV-positive and
HIV-negative patients had squamous cell carcinoma),
hydronephrosis, or lymph node disease (Table 1).
Treatment
Radical radiotherapy
In total, 291 HIV-negative patients (89.8%) and 47
HIV-positive patients (79.7%) received radiation doses
Figure 1. This is a flow chart of the study population. HIV indi-
cates human immunodeficiency virus.
Table 1. Demographic and Clinical Characteristics According to Human Immunodeficiency Virus Status
HIV Status
Positive Negative Total
Characteristic No. % No. % No. % P
Entire cohort 59 15.4 324 84.6 383 100
Median age, y 41 50 <.001a
Age group, y <.001a
<40 27 45.8 55 17 82 21.4
40-49 20 33.9 100 30.9 120 31.3
50-59 11 18.6 105 32.4 116 30.3
‡60 1 1.7 64 19.8 65 17
Histology .57
Squamous 56 94.9 300 92.6 356 93
Adenocarcinoma 1 1.7 15 4.6 16 4.2
Other 2 3.4 9 2.8 11 2.9
FIGO stage .009a
IB1 0 0 3 0.9 3 0.8
IB2 0 0 3 0.9 3 0.8
IIA 0 0 4 1.2 4 1
IIB 10 16.9 99 30.6 109 28.5
IIIA 0 0 2 0.6 2 0.5
IIIB 49 83.1 213 65.7 262 68.4
Hydronephrosis (IIIB only) 9 15.3 31 9.6 40 10.4 .51
Lymph nodes present 15 25.4 61 18.8 76 19.8 .28
Para-aortic/common iliac lymph nodes 4 6.8 23 7.1 27 7 1.0
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; HIV, human immunodeficiency virus; SD, standard deviation.
a Significant (P < .05).
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68 Gy EQD2 (P ¼ .03). Table 2 provides details of the
radiation received. Of note, 6 of 7 patients who had CD4
counts <200 cells/lL completed 68 Gy EQD2. Of 27
patients who received extended-field radiotherapy, 25
completed 45 Gy. The 2 patients who did not complete
the intended PAN treatment were HIV positive. Two
HIV-negative patients had data missing on treatment
time. The overall treatment time for those who completed
both the EBRT component and the HDR component
was 55 days for all HIV-positive patients, and only 1
patient in the HIV-negative group was treated for >55
days. The mean overall treatment time for HIV-positive
patients was 44 days compared with 41 days in the HIV-
negative group (P < .01) (Table 2). Reasons for incom-
plete EBRT (<45 Gy) included hypofractionated regi-
mens, poor attendance, refusal to complete, renal failure,
neutropenia, grade 3 GIT toxicities, and development of
metastatic disease (Table 2).
Concurrent chemotherapy
Of 284 HIV-negative patients who began platinum-
based chemotherapy, 212 (74.6%) completed 4 cycles.
Of the 49 HIV-positive patients who commenced chemo-
therapy, only 26 (53.1%) completed 4 cycles of plati-
num-based chemotherapy (P ¼ .01) (Table 3). Eight of
19 patients who were receiving HAART (42.1%) and 18
of 40 patients who were not receiving HAART (45%)
managed to complete adequate chemotherapy. Those
who completed chemotherapy had higher median CD4
counts than those who did not (416 cells/lL vs 311 cells/
lL; P¼ .02).
Fifty patients (40 HIV-negative patients and 10
HIV-positive patients) received no chemotherapy because
of poor renal function, poor performance status, a CD4
count <200 cells/lL, active pulmonary tuberculosis, or
hypofractionated radiotherapy. Renal dysfunction was the
most common reason why chemotherapy was not com-
pleted. Other contributing factors were poor compliance,
incomplete EBRT, discovery of active pulmonary tuber-
culosis, discovery of a positive HIV test and subsequent
low CD4 count, hematologic toxicity, persistent grade 3
GIT toxicity, and, in 1 patient, a diagnosis of small cell
carcinoma (that patient received a different regimen) (see
Table 4).
Completion of ‡45 Gy external-beam
radiotherapy/‡18 Gy high-dose-rate
brachytherapy/4 cycles of chemotherapy
Among the 49 HIV-positive patients and 284 HIV-
negative patients who initiated curative-intent chemora-
diation, 22 HIV-positive patients (44.9%) and 199 HIV-
Table 2. Completion of Radiotherapy According to Human Immunodeficiency Virus Status
HIV Status
Positive Negative Total
Radiotherapy Variable No. % No. % No. % P
Entire cohort 59 15.4 324 84.6 383 100
EBRT dose: MeanSD, Gy 47.74.6 49.16.7 .05a
‡45 Gy EBRT 50 84.7 309 95.4 359 93.7 .05a
‡18 Gy HDR 47 79.7 293 90.4 340 88.8 .051
‡45 Gy EBRT plus 18 Gy HDR 45 76.3 284 87.7 329 85.9 .026a
‡68 Gy EQD2 47 79.7 291 89.8 338 88.3 .026
a
EQD2 dose: MeanSD, Gy 72.413.7 75.110.9 .094
Overall treatment time: MeanSD, db 443.60 403.83 <.01a
Reasons for incomplete EBRT <45Gy
Entire cohort 9 37.5 15 62.5 24 100
Patient refused to complete 2 25 3 21.4 5 22.7
Developed metastatic disease 2 25 — — 2 9.1
Infection 2 25 — — 2 9.1
Renal failure 1 12.5 2 14.3 3 13.6
Poor attendance — — 2 14.3 2 9.1
Persistent neutropenia — — 1 7.1 1 4.5
GI toxicity grade3/4 — — 2 14.3 2 9.1
Hypofractionated RT 2 12.5 5 28.6 7 22.7
Abbreviations: EBRT, external-beam radiotherapy; EQD2, equivalent dose in 2-Gy fractions; GI, gastrointestinal; Gy, grays; HDR, high-dose-rate brachytherapy;
HIV, human immunodeficiency virus; RT, radiotherapy; SD, standard deviation
a Significant (P < .05).
b For those who completed treatment with 45 Gy EBRT plus 18 Gy HDR.
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negative patients (70.4%) completed treatment (P ¼
.001) (Table 3).
Response to Treatment
At the time of EUA and at the 6-week follow-up visit, the
numbers of patients available for evaluation were reduced
because of incomplete treatment, loss to follow-up, refer-
ral back to distant medical centers, and death. Of the 383
patients analyzed, 370 patients (309 HIV-negative
patients and 51 HIV-positive patients) had EUA before
the initiation of brachytherapy; 108 HIV-negative
patients (35%) but only 10 HIV-positive patients
(19.6%) had a complete response (P¼ .008) (Table 4).
At 6 weeks, only 326 patients (279 HIV-negative
patients and 47 HIV-positive patients) presented for fol-
low-up. Of those, 160 HIV-negative patients (57.3%) but
only 18 HIV-positive patients (38.3%) had a documented
complete response (P ¼ .02) (Table 4). In logistic regres-
sion models that were adjusted for age, HIV status, disease
stage, and completion of treatment, the factors associated
with an incomplete response were stage IIIB disease (OR,
2.39; 95% CI, 1.45-3.96) and receiving <68 Gy EQD2
(OR, 3.14; 95% CI, 1.24-7.94). Table 5 provides the
details of each component of treatment. The CD4 count
was not included in the model, because 52 of 59 HIV-
positive patients had CD4 counts>200 cells/lL.
DISCUSSION
Among the women with cervical cancer in our study,
those who were HIV-positive presented at a younger age
and with more advanced stage disease than their HIV-
negative counterparts. Most patients were able to com-
plete adequate EBRT and HDR brachytherapy; however,
although the HIV-positive patients received less radiation
and substantially less chemotherapy than the HIV-nega-
tive patients, disease stage and completing radiation were
the only independent predictors of response. In particular,
the completion of brachytherapy was a vital component of
treatment.
The demographic and clinical differences we
observed between HIV-positive patients and HIV-
Table 3. Completion of Chemotherapy According to Human Immunodeficiency Virus Status
HIV Status
Positive Negative Total
Chemotherapy Variable No. % No. % No. % P
Entire cohort 59 324 383 100
Commenced chemotherapy 49 83 284 87.3 333 86.9
Received ‡4 cycles cisplatin or carboplatin 26 53.1 212 74.6 238 71.5 .002a
Received ‡4 cycles of cisplatin 23 46.9 191 67.2 214 57.3)
No. of cycles
0 10 16.9 40 12.7 50 13.1
1 6 10.2 15 4.6 21 5.5
2 11 18.6 26 8.3 37 9.7
3 6 10.2 31 9.6 37 9.7
Received 4 cycles of chemotherapy
with 45 Gy EBRT plus 18 Gy HDR
22 44.9 199 70.9 221 66.4 .001a
Reasons for incomplete platinum-based chemotherapy
Entire cohort 23 72b 95 100
Renal dysfunction 15 65.2 54 75 69 72.6
Incomplete EBRT 3 13 5 6.9 8 8.4
Active PTBc 1 4.3 — — 1 1.1
CD4 count <200 cells/lLd 1 4.3 — — 1 1.1
Poor compliance — — 2 2.8 2 2.1
Hematologic toxicity 2 8.7 4 5.5 6 6.3
Gastrointestinal toxicity — — 4 5.5 4 4.2
Alternate chemotherapy (small cell) — — 1 1.4 1 1.1
Infection 1 4.3 2 2.8 3 3.2
Abbreviations: EBRT, external-beam radiotherapy; Gy, grays; HDR, high-dose-rate brachytherapy; HIV, human immunodeficiency virus; PTB, pulmonary
tuberculosis.
a Significant (P < .05).
b Complete data were available on 72 of 73 HIV-negative patients.
c PTB was diagnosed after treatment commenced.
dHIV status was established only after treatment commenced.
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negative patients with cervical carcinoma (eg, younger age
and more advanced disease at presentation) have been
reported previously.14 Few of our HIV-positive patients
knew their HIV status before their cancer diagnosis, and
few had commenced HAART before their first oncology
visit. Because the median CD4 count among the HIV-
positive patients was 354 cells/lL, and the majority had
counts >200 cells/lL, immunocompetence did not
appear to reduce the risk of cervical carcinoma as it does
the risks of Kaposi sarcoma and non-Hodgkin
lymphoma.15
Our findings are similar to those reported from
studies of tolerance for chemoradiation among HIV-posi-
tive patients with anal cancer.16,17 Oehler-Janne et al
reported that significantly fewer HIV-positive patients
(30%) than HIV-negative patients (64.2%) received the
prescribed chemotherapy. Hammad et al also observed
that 89% of HIV-negative patients but only 45% of HIV-
positive patients completed chemotherapy at the planned
dose. What is clear is that the chemotherapy component is
the most difficult aspect of chemoradiation therapy for
HIV-positive patients to complete. In our study, we noted
that patients who failed to complete chemotherapy had
lower median CD4 counts than those who completed
chemotherapy. We were surprised to note that renal dys-
function, and not myelosuppression or GIT toxicity, was
the most common reason for HIV-positive patients to dis-
continue therapy. We simply may have a conservative and
cautious approach to chemotherapy in choosing 50 mL/
minute as the cutoff GFR for giving cisplatin. If cisplatin
is commenced and renal function deteriorates, then we do
attempt to reduce the dose to either 25% or 50% of the
planned dose in an attempt to continue with weekly dos-
ing. Some institutions use a lower standard dose of cispla-
tin up front, but the benefit of this approach has yet to be
confirmed in prospective efficacy studies.18
The benefit of chemotherapy in patients with stage
IIIB cervical cancer also is less than clear. The most recent
meta-analysis of treatment for cervical cancer noted that,
among patients with stage IIIB disease, the incremental
benefit of chemoradiation over radiation alone was only
3%.9 The numbers of patients with stage IIIB disease in
those studies were small, however; and further studies of
such patients are awaited. In our cohort, completion of
Table 4. Response at Examination Under Anesthesia and at 6 Weeks According to Human
Immunodeficiency Status
HIV Status
Positive Negative Total
Response No. % No. % No. % P
Entire cohort 59 324 383 100
Underwent EUA 51 86.4 309 95.4 360 94
Complete response at EUA 10 19.6 108 35 118 32.8 .036a
Attendance at 6 wk 47 79.7 279 86.1 326 85.1
Complete response at 6 wk 18 38.3 160 57.3 178 54.6 .018a
Abbreviations: EUA, examination under anesthesia; HIV, human immunodeficiency virus.
a Significant (P < .05).
Table 5. Factors Associated With Partial Response Versus
Complete Response at Six Weeks
Variable OR 95% CI P
HIV status
Negative 1.00 Referent
Positive 1.71 0.85-3.36 .135
FIGO stage
IB1-IIIA 1.00 Referent
IIIB 2.41 1.45-4.00a .001a
Age group, y
<40 1.00 Referent
40-49 0.87 0.44-1.69 .67
50-59 0.68 0.35-1.33 .26
‡60 0.51 0.22-1.17 .11
Completion of EBRT, Gy
‡45 1.00 Referent
<45 1.18 0.36-3.89 .78
Completion of HDR, Gy
‡18 1.00 Referent
<18 3.13 1.28-7.61 .012a
Completion of chemotherapy
‡4 Cycles 1.00 Referent
<4 Cycles 0.62 0.36-1.06 .08
Abbreviations: CI, confidence interval, EBRT, external-beam radiotherapy;
FIGO, International Federation of Gynecology and Obstetrics; Gy, grays;
HDR, high-dose-rate brachytherapy; HIV, human immunodeficiency virus;
OR, odds ratio.
a Significant (P < .05).
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chemoradiation had no greater impact on response at 6
weeks than radiation alone. Because most of our HIV-
positive and HIV-negative patients had stage IIIB disease,
it may be reasonable to omit chemotherapy; doing so may
enable us to deliver a full dose of radiation in a timely
manner.
The few studies of treatment and outcomes for
HIV-positive patients receiving radiotherapy for cervical
carcinoma have reported variable results. Shrivastava et al
described a cohort of 42 HIV-positive patients who
received treatment at the Tata Memorial Hospital in
India.19 In that study, only 22 patients completed EBRT,
and only 50% had a complete response at 6 weeks. Mood-
ley and Mould from KwaZulu/Natal, South Africa,
reported that only 53% of HIV-positive patients were
able to complete treatment (including surgery or radio-
therapy),20 in part because of resource constraints in the
region. Gichangi et al in Nairobi, Kenya, observed that
HIV-positive patients did not differ from HIV-negative
patients in dose received but had significantly poorer out-
comes at 4 months and 7 months.21 In their final analysis,
9 of 24 patients had residual disease at follow-up (adjusted
risk ratio, 6.2; 95% CI 1.4-28.1). In our data, HIV-posi-
tive patients had worse responses than HIV-negative
patients; however, in logistic regression models that
adjusted for age, HIV status, disease stage, and comple-
tion of treatment, the only significant factors were
advanced stage and completion of radiation. The model
conveyed that the HIV-positive patients had poorer
responses only because they were more likely to present
with advanced disease and less likely to complete treat-
ment than the HIV-negative patients.
Although our study is 1 of the largest to compare
cervical cancer outcomes among HIV-positive and HIV-
negative women, it has several important limitations. It
included all women with HIV from a region where the
disease is endemic; however, its HIV-positive sample con-
sisted of only 59 women. Therefore, the study may have
been underpowered to detect differences in some charac-
teristics and outcomes. Another limitation is that the data
were collected retrospectively from the medical charts.
However, all patients were treated according to the same
treatment principles and guidelines.
Currently, we are conducting further analyses of
treatment-associated toxicity and temporal trends in tox-
icity in our cohort. In addition, the goal of the current
study was to report on completion of and short-term
response to treatment. Data on overall survival are matur-
ing and will be reported in future publications.
In conclusion, despite the small numbers, our find-
ings suggest that good medical care of HIV-positive
patients can enable patients to complete treatment for
locally advanced cervical cancer. The current results also
highlight the importance of radiation therapy. Thus, as
we await the publication of results from the randomized
chemoradiation trials in progress among both patients
with FIGO stage IIIB disease and patients with HIV, we
will concentrate on enabling our patients to complete
their radiation therapy.
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HIV Status and Acute Hematologic Toxicity Among
Patients With Cervix Cancer Undergoing
Radical Chemoradiation
Hannah M. Simonds, MBChB, MRCP, FRCR,* Alfred I. Neugut, MD, PhD,Þþ§
and Judith S. Jacobson, DrPH, MBAÞþ
Introduction: Women infected with the human immunodeficiency virus (HIV) have a
higher risk of developing cervix carcinoma than do other women who are thought to be
more vulnerable to acute toxicities during chemoradiation. We compared HIV-positive/
HIV-negative patients with cervix carcinoma at a single institution with respect to cancer
treatment toxicities.
Methods and Materials: Among patients with stage Ib1-IIIb invasive cervical carcinoma
who received radiation or chemoradiation with curative intent, we evaluated demographic
and clinical characteristics of HIV-positive and HIV-negative patients. Treatment regimens
were documented and toxicities scored as per Radiation Therapy Oncology Group guide-
lines. We developed logistic regression models for the associations of grade 3/4 toxicities
with HIV status.
Results: Complete data were available on 213 patients, including 36 (16.8%) who were
HIV positive. More than 85% of both HIV-positive and HIV-negative patients received a
minimum of 68-Gy equivalent dose in 2-Gy-fraction external beam and high-dose-rate
brachytherapy. More HIV-positive than HIV-negative patients were prescribed radiation
alone (38.9% vs 24.29%, P = 0.01), experienced at least 1 grade 3/4 toxicity (38.9% vs
26.6%), or developed grade 3/4 leucopenia (30.6% vs 10.2%, P = 0.003).
In a multivariable model, patients who developed a grade 3/4 toxicity were 4 times as likely
to have received chemotherapy (odds ratio, 4.41 [95% confidence interval, 1.76Y11.1];
P = 0.023) and twice as likely to be HIV positive (odds ratio 2.16 [95% confidence interval,
0.98Y4.8]; P = 0.05) as women who did not experience such toxicities.
Conclusions: HIV-positive patients with cervical carcinoma received adequate radio-
therapy but were less likely than HIV-negative patients to complete chemotherapy. FewHIV-
positive or HIV-negative patients who received radiotherapywithout chemotherapy experienced
grade 3/4 toxicity. However, among patients who received chemotherapy, thosewhowere HIV
positive were more likely than others to experience hematologic toxicity.
Key Words: Cervical cancer, Human immunodeficiency virus, AIDS-defining
malignancy, Radiation, Chemoradiation, Toxicity
ORIGINAL STUDY
International Journal of Gynecological Cancer & Volume 25, Number 5, June 2015 1
*Division of Radiation Oncology, Tygerberg Hospital/University
of Stellenbosch, Stellenbosch, South Africa; †Herbert Irving Com-
prehensive Cancer Centre, Columbia University, New York, NY;
‡Department of Epidemiology, Mailman School of Public Health,
Columbia University, New York, NY; and §Division of Oncology,
ColumbiaUniversityCollege of Physicians and Surgeons,NewYork,NY.
Address correspondence and reprint requests to Hannah Simonds,
Division of Radiation Oncology, Tygerberg Hospital, Private Bag
X1, Tygerberg 7505, South Africa. E-mail hsimonds@
googlemail.com.
The project described was supported by Award No. D43CA153715
from the National Cancer Institute. The content is solely the
responsibility of the authors and does not necessarily represent
the official views of the National Cancer Institute or the National
Institutes of Health.
The authors declare no conflicts of interest.
Copyright * 2015 by IGCS and ESGO
ISSN: 1048-891X
DOI: 10.1097/IGC.0000000000000441
Copyright © 2015 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
Stellenbosch University https://scholar.sun.ac.za
Received July 2, 2014, and in revised form February 17, 2015.
Accepted for publication February 17, 2015.
(Int J Gynecol Cancer 2015;25: 00Y00)
Cervical carcinoma remains one of the leading causes ofcancer and cancer mortality among women in the de-
veloping world, including women infected concurrently with
human papillomavirus (HPV) and human immunodeficiency
virus (HIV).1 Most research on the co-occurrence of the 2
conditions has focused on incidence. Recent studies suggest
that by prolonging the life expectancy of HIV-positive women,
antiretroviral therapy (ART) may have actually contributed to
rising incidence rates of cervix carcinoma.2
Treating patients with the 2 conditions challenges the
oncology and infectious disease teams. Treatment involves
balancing oncological therapy, concomitant ART, and anti-
microbials, and trying to cure the underlying malignancy, to
control HIV-related opportunistic infections, and to minimize
treatment toxicities. However, very little research has dealt
with the effects of HIV status on cervix carcinoma treatment
and its outcomes. In a previous study of patients with cervix
cancer treated between 2007 and 2010, we found that 79.7%
of HIV-positive patients and 89.8% of HIV-negative patients
received adequate radiation and that 44.9% of HIV-positive
patients vs 70.9% of HIV-negative patients completed both
radiation and 4 or more cycles of platinum-based chemo-
therapy.3 Poor response at 6 weeks was found to be related to
stage IIIb disease and inadequate radiation. The aim of the
current study was to compare treatment toxicities in another
cohort (overlapping the first) of HIV-positive and HIV-
negative patients whose treatment toxicity data were col-
lected prospectively.
METHODS AND MATERIALS
Patient Records
For this prospective cohort study, we reviewed the
charts of all patients diagnosed as having stage Ib1 to IIIb
invasive cervical carcinoma who were categorized as HIV
positive or HIV negative, received radiation or chemoradia-
tion with curative intent, and had complete toxicity data be-
tween November 2009 and December 2011 at the Division
of Radiation Oncology, Tygerberg Hospital. Patients who
underwent primary surgery were excluded. Ethical approval
was obtained from the University of Stellenbosch human
ethics committee.
In late 2009, our oncology clinic consultant introduced
clinic residents to the use of a modified Radiation Therapy
Oncology Group toxicity score sheet that included hemato-
logic, renal, gastrointestinal, urinary, skin, and weight pa-
rameters.4 The team then began reviewing charts, recording
demographic and clinical characteristics of the patients, and
collecting toxicity data at the time of treatment. The con-
sultant reviewed the completed sheets weekly. We determined
whether or not the HIV-positive patients had commenced
ART before treatment of cervix cancer and recorded their
initial CD4 cell count. Treatment regimens, including external
beam radiation therapy (EBRT) dose, high-dose-rate (HDR)
brachytherapy dose, and chemotherapy cycles, were docu-
mented. The total doses of EBRT and HDR were calculated
using equivalent dose in 2-Gy (EQD2) fraction formulas.5
Treatment
The radiotherapy protocols used for the study partici-
pants have been previously reported.3 Patients without con-
traindications received 46- to 50-Gy external beam radiation
in 23 to 25 fractions, using conformal 3-dimensional planning
and 18-MVenergy, 4-field arrangement. This was followed by
20- to 25-Gy HDR intracavitary brachytherapy in 4 to 5
fractions. A straight intrauterine source and standard plans for
the appropriate intracavitary length were used. At the time of
the study, no image-guided brachytherapy was available. For
patients who had a history of extensive abdominal surgery or
were HIV positive, the daily dose per fraction was dropped to
1.8 Gy. The absolute minimum total dose considered ade-
quate was 68-Gy EQD2 (45-Gy external beam radiotherapy
and 18 Gy in 3-fraction HDR brachytherapy).
If renal function was allowed, 40 mg/m2 cisplatin was
given weekly; if calculated glomerular filtration rate or
ethylenediaminetetraacetic acid glomerular filtration rate was
less than 50 mL/min, carboplatin area under the curve2
weekly was given. No dose modifications were made for CD4
cell count unless it fell below 200, in which case chemo-
therapy was omitted. Because of pressure on the radiotherapy
waiting list, in some cases of stage IIIB disease, chemotherapy
was omitted and a hypofractionated regimen of 40.05 Gy in
15 fractions, or 42.72 Gy in 16 fractions, was used with
standard HDR brachytherapy. The same fractionation was
also used for patients with poor renal function or poor per-
formance status.
At our institution, patients with locally advanced cervix
carcinoma are routinely tested for HIV at first presentation.
All HIV-positive patients are scheduled for HPV screening
annually; thus, very few develop locally advanced disease.
Almost all of the patients in this cohort were diagnosed as
having HIVat the time of the cervix cancer diagnosis. Patients
with cervix carcinoma who test positive start receiving ART
either just before or as soon as possible after commencing
radiation treatment. Antiretroviral therapy at the time of the
study included triple therapy with lamivudine, efavirenz, and
tenofivir, unless the creatinine clearance was low, in which
case the patient received stavudine instead of tenofivir. Every
HIV-positive patient commencing radiation or chemoradiation
receives concurrent cotrimoxazole. Because HIV infection is a
large burden for tertiary centers, many of our patients receive
their HIV care at community health centers, andwewere unable
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to obtain data on viral load, compliance, medication changes,
and ART toxicities for this study.
Statistics
The statistical significance of differences in demo-
graphic factors, clinical parameters, and toxicity between
HIV-positive and HIV-negative patients was evaluated by
means of t tests for continuous variables and W2 tests for
categorical variables. Multivariable logistic regression models
were developed to analyze the risk of developing a grade 3/4
toxicity controlling for HIV status, total dose of radiation, and
prescription of chemotherapy. Results were expressed as odds
ratios (ORs) with 95% confidence intervals (CIs). All tests
were 2 sided, and P values of 0.05 or less were considered
significant. Data were analyzed using the SPSS Statistics
software program (version 21.0; SPSS, Inc, Chicago, IL)
RESULTS
Patient Characteristics
A total of 259 patients with cervical carcinoma stages
IB to IIIB commenced radical radiotherapy during the study
period; 46 patients had no toxicity data. Of the patients with
no toxicity scores, 36 were HIV negative and all completed
their prescribed radiotherapy; of the 10 patients who were
HIV positive, 6 completed radiotherapy.
Complete toxicity data were available on 213 patients;
36 (16.8%) were HIV positive. The HIV-positive patients
were younger than the HIV-negative patients but did not differ
from them with respect to the prevalence of either squamous
cell carcinoma or stage IIIB disease (see Table 1). The median
CD4 cell count of the HIV-positive patients was 341 (range,
33Y790); 30 patients had a CD4 greater than 200. Sixteen
patients beganART before the commencement of radiotherapy.
All others commenced ARTeither during or after radiotherapy.
Chemoradiation
More than 85% of both HIV-positive and HIV-negative
patients received external beam and HDR brachytherapy,
totaling more than 68-Gy EQD2. Significantly more HIV-
positive than HIV-negative patients were prescribed radia-
tion alone (38.9% vs 24.3%, P = 0.01; see Table 2). The
reasons for not commencing chemotherapy in the HIV-
positive group included active pulmonary tuberculosis (n = 2),
a CD4 cell count less than 200 (n = 6), and prescription of a
hypofractionated radiation regimen (n = 5). A similar propor-
tion of the HIV-negative patients (n = 33) also received the
hypofractionated radiotherapy regimen without chemotherapy.
Of the 22 (61.1%) HIV-positive patients who were
prescribed chemoradiation, 15 (68.9%) completed 4 or more
cycles of chemotherapy and received adequate radiother-
apy (see Table 2). Of the 177 HIV-negative patients, 137
(75.7%) commenced chemoradiation and 129 (94.2%) com-
pleted it (P = 0.05).
Among both HIV-negative and HIV-positive patients,
62% who received 4 or more cycles of chemotherapy had a
reduction in dose to either 30 or 20 mg/m2 cisplatin because
their creatinine clearance had fallen by10%or below50mL/min.
These criteria are strictly adhered to in the clinic to minimize
risk of renal toxicity.
Toxicity
Fourteen HIV-positive patients (38.9%) and 47 HIV-
negative patients (26.6%) had at least 1 grade 3Y4 toxicity
(P = 0.16; Table 3). Eleven HIV-positive patients (30.6%) but
only 18 HIV-negative patients (10.2%) developed grade 3Y4
leukopenia (P = 0.003). All patients whose white cell count
dropped substantially had received chemotherapy.
Looking only at hematologic toxicity, the HIV-positive
patients were also more likely to develop grade 2 anemia and
neutropenia (Table 4). HIV status was not associated with
increased gastrointestinal, renal, skin, or weight toxicities.
TABLE 1. Demographic and clinical characteristics of patients with cervix carcinoma, by HIV status
Characteristic
HIV Status
PPositive Negative Total
No. of patients (%) 36 (16.9) 177 (83.1) 213 (100)
Age, y G0.001*
Median 41 50 49
Range 26Y62 23Y79 23Y79
Histology, n (%) 0.27
Squamous 34 (94.4) 163 (91.6) 197 (92.1)
Adenocarcinoma 1 (2.8) 5 (2.8) 6 (2.8)
Other 1 (2.8) 9 (5.6) 10 (5.1)
FIGO stage, n (%) 0.55
Ib1-IIIa 9 (25) 56 (31.6) 65 (30.5)
IIIb 27 (75) 121 (68.4) 148 (69.5)
*P e 0.05 considered significant.
FIGO, International Federation of Gynecology and Obstetrics.
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Fifty-seven patients were prescribed radiation alone;
they were prescribed either 1.8- or 2-Gy fractionated EBRT,
or hypofractionated EBRT, and brachytherapy. Overall, only
8 (14.0%) of these patients had a recorded grade 3Y4 toxicity
compared with 54 patients of the 159 (34.0%) who received
any chemotherapy (P = 0.03). Four HIV-negative patients had
grade 3Y4 anemia and 2 had grade 3Y4 creatinine toxicity.
Two HIV-positive patients had grade 3 anemia.
In a multivariable model that included HIV status, total
dose of radiotherapy received, and prescription of chemother-
apy, patients who developed a grade 3Y4 toxicity were 4 times
as likely to have received chemotherapy as patients without
such a toxicity (OR, 4.41 [95% CI, 1.76Y11.1]; P = 0.002). In
the same model, patients who developed a grade 3Y4 toxicity
were twice as likely to be HIV positive as patients who did not
(OR, 2.16 [95% CI, 0.98Y4.8]; P = 0.057). As expected, those
who received less than 68-Gy EQD2 showed a lower risk of
toxicity, although this was not significant (Table 5).
DISCUSSION
Among 213 patients with cervical carcinoma in this
study, HIV-positive patients generally received adequate ra-
diotherapy but were less likely than HIV-negative patients to
complete chemotherapy. These results are similar to those of
our previously reported study.2 Nearly 40% of HIV-positive
patients in the current study either were not prescribed con-
current chemotherapy at the outset of treatment because of
low CD4 counts or were prescribed a hypofractionated regi-
men. Very few HIV-positive or HIV-negative patients who
TABLE 3. Grade 3-4 toxicities by HIV status
Toxicities
HIV Status
P
Positive Negative Total
n % n % n %
No. of patients 36 16.9 177 83.1 213 100
Overall 14 38.9 47 26.6 61 28.6 0.157
Leucopenia 11 30.6 18 10.2 29 14.0 0.003*
Thrombocytopenia 1 2.8 0 0 1 0.5 0.169
Anemia 3 8.3 12 6.8 15 7.0 0.723
Neutropenia 3 8.3 7 4.0 10 4.7 0.378
Creatinine 0 0 4 2.3 4 1.9 1.0
Nausea 1 2.8 14 8.0 15 7.0 0.476
Vomiting 1 2.8 4 2.3 5 2.3 1.0
Diarrhea 1 2.8 5 2.8 6 2.8 1.0
Cystitis 0 0.0 1 0.6 1 0.5 1.0
Skin 1 2.8 2 1.1 3 1.4 1.0
Weight 0 0.0 0 0.0 0 0.0 1.0
*P e 0.05 considered significant.
TABLE 2. Completion of treatment by HIV status
Treatment
HIV Status
P
Positive Negative Total
n % n % n %
No. of patients 36 16.9 177 83.1 213 100
Completed 9EQD2 68 Gy (all patients) 31 86.1 160 89.8 191 89.2 0.55
Prescribed EBRT alone 14 38.89 43 24.29 57 26.76 0.01*
Completed 9EQD2 68 Gy 10 71.4 32 74.42 42 73.68 1.0
Prescribed chemoradiation 22 61.1 134 75.7 157 0.10
9EQD2 68 Gy + 4 cycles of weekly platinum 15 68.18 117 87.31 132 0.05*
*P e 0.05.
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received EBRT (whether hypofractionated or prescribed in
conventional 1.8- or 2-Gy fractions) and HDR brachytherapy
without chemotherapy experienced a grade 3Y4 toxicity.
Unfortunately, in the developing countries where cer-
vical cancer and HIV are common, many patients have no
access to radiation therapy or have access only to low-energy
machines, such as Co60, which lack the skin-sparing benefits
of the 18-MV treatment prescribed in this study. They also
lack access to 3-dimensional conformal planning with com-
puted tomographyYbased techniques, which allow beam
shaping with multileaf collimators, thereby decreasing dose to
normal tissues.
The literature regarding radiotherapy toxicity in HIV-
positive patients with cervical carcinoma is very limited.
Gichangi et al6 found that more than 50% of both HIV-
positive and HIV-negative patients in Kenya who received
radiation therapy experienced grade 3Y4 toxicity. However,
those patients were treated with large parallel-opposed fields
with low-energy Co60. In a survey in Uganda, 12% of patients
experienced skin, 7% gastrointestinal, and 3% genitourinary
toxicity.7 A study at Tata Memorial Medical Centre in India
retrospectively examined radiotherapy toxicity among HIV-
positive patients.8 Of 32 patients who commenced radical
EBRT, 22 completed treatment; grade 3Y4 gastrointestinal
toxicity occurred in 14% of patients and 27% had a grade 3Y4
toxicity leading to treatment delays. These reports did not
include enough details about the patient population and the
treatment to permit direct or full comparisons with our own
cohort. Although those of our patients who received radiation
alone had very few toxicities, the overall grade 3Y4 toxicity
rate approached 30%, and nearly 40% of HIV-positive pa-
tients who received chemoradiation experienced such toxic-
ities, most of them hematologic. It should probably not be
surprising that HIV-positive patients who receive chemother-
apy on top of pelvic radiation develop leukopenia. An ongoing
prospective randomized study sponsored by the International
Atomic Energy Agency is currently comparing outcomes
among HIV-positive patients with cervical cancer receiving
either chemoradiation or radiation alone. If completed, this
study would be the first randomized trial of the 2 treatment
modalities in HIV-positive patients; however, it is uncertain if
data collection will be completed (Charlotte Maxeke Johan-
nesburg Academic Hospital, personal communication).
The literature on chemoradiation toxicity among HIV-
positive patients with pelvic malignancies is sparse. Most
reports focus on anal carcinoma. Although patients with anal
carcinoma are not comparable to patients with cervix carci-
noma and have different chemotherapy regimens, HIV-
positive patients are less likely to complete chemoradiation
for either cancer than HIV-negative patients.9Y11
We were unable to evaluate the effects of ART on pa-
tients receiving chemoradiation because most of our patients
TABLE 5. Factors associated with grade 3/4 toxicity
OR 95% CI Lower 95% CI Higher P
HIV status
Negative 1.0 Referent
Positive 2.16 .98 4.8 0.05*
Total EQD2
Q68 Gy 1.0 Referent
G68 Gy 0.44 0.15 1.33 0.15
Concurrent chemotherapy
No 1.00 Referent
Yes 4.41 1.76 11.1 0.023*
*P e 0.05 considered significant.
TABLE 4. Grade 2 hematologic toxicities by HIV status
Toxicity
HIV Status
P
Positive Negative Total
n % n % n %
Leucopenia 10 27.7 47 26.6 57 26.8 0.839
Thrombocytopenia 2 5.5 3 1.7 5 2.35 0.199
Anemia 23 63.8 71 40.1 94 44.1 0.01*
Neutropenia 7 19.4 15 8.5 22 10.3 0.02*
*P e 0.05 considered significant.
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commenced ART either just before or during their cancer
treatment. Some studies have shown an association of ART
with adverse changes in hematologic parameters. However,
we are unable to draw conclusions regarding the role of ART
in leucopenia in the few HIV-positive patients in our cohort.
Of the HIV-negative patients in our cohort, nearly 95%
completed chemoradiation, and more than 25% had a recorded
grade 3Y4 toxicity. These proportions are comparable to those
in international studies of chemoradiation vs radiation alone.
In a study by Keys et al,12 90% of patients receiving weekly
cisplatin completed their prescribed treatment and 35% de-
veloped grade 3Y4 toxicity. In the study published by Rose
et al,13 93% of patients completed 4 or more cycles of weekly
cisplatin and received adequate radiation. The patients in our
study cohort achieved comparably high rates of completion
of radiation due, in part, to the use of high-energy megavol-
tage radiation, multileaf collimation, and conformal volumes.
However, many of our patients required a chemotherapy dose
reduction, probably because they were in poorer overall health
than patients in developed countries. In a phase 1 study by
Nyongesa et al14 in a patient population similar to ours, the
maximum tolerated dose of cisplatinwas found to be 25mg/m2.
Further in-depth study of toxicities and dose reductions in
limited resource settings is urgently needed.
A limitation of this study is the relatively small number
of HIV-positive patients in our sample; however, we included
consecutive patients who met the eligibility criteria on our
analysis, and ours is one of the largest HIV-positive cohorts in
the published literature. Ten patients who were HIV positive
did not have toxicity data recorded, which may introduce bias
into the statistical results. Another limitation is that several
different clinicians assessed and recorded the toxicities; they
may not have used consistent criteria, but their use of a de-
tailed standard toxicity sheet may have helped to minimize
inconsistencies. A strength of the study is that both HIV-
positive and HIV-negative patients adhered to our radiation
treatment protocols.
The challenge is to find ways to help patients with
cervical cancer, with and without HIV, in the many parts of the
developing world where aging equipment or no equipment for
radiation therapy is available. Unless screening becomes
sufficiently widespread to downstage detected disease, or
until HPV vaccination eliminates the carcinogenic strains of
HPV, how to provide better treatment for the patients who
need it most will remain a conundrum for health policy.
CONCLUSIONS
This study found that HIV-positive patients undergoing
curative chemoradiation for cervical cancer had a higher risk
of developing acute hematologic toxicity than did patients
treated with radiation alone. Oncologists should exercise
caution in the use of chemotherapy for such patients, in
particular in the developing world setting where patients
overall have poorer health and limited access to health care
services. The data do not definitively support omitting che-
motherapy from the treatment protocol for HIV-positive pa-
tients because only 36 of our 213 patients were HIV positive.
Overall, this cohort of HIV-positive and HIV-negative patients
tolerated radiation alone very well, most likely because they
were treated with state-of-the-art equipment and radiation
planning techniques. In the developed world setting, use of
advanced techniques such as intensity-modulated radiation
therapy may be beneficial in further reducing dose to normal
tissue. However, we have as yet no information about long-
term treatment effects, recurrence, or survival in our pa-
tients, and studies of those end points among patients with
cervical cancer with and without HIV in the developing world
are much needed. Recurrence and survival data will be
reported on a larger cohort from this institution. Randomized
trials will hopefully provide data on how to maximize efficacy
while minimizing adverse effects.
ACKNOWLEDGMENTS
We thank the patients and staff at Tygerberg Hospital
for their contribution to this study.
REFERENCES
1. Awolude OA, Morhason-Bello IO, Denny LA, et al. Human
papillomavirus infection and related cancers in sub-Saharan
Africa: burden and tools for prevention. Vaccine. 2013;
31(suppl 5):viiYx.
2. Einstein MH, Phae¨ton R. Issues in cervical cancer incidence and
treatment in HIV. Curr Opin Oncol. 2010;22:449Y455.
3. Simonds HM, Wright JD, Du Toit N, et al. Completion of and
early response to chemoradiation among human
immunodeficiency virus (HIV)Ypositive and HIV-negative
patients with locally advanced cervical carcinoma in South
Africa. Cancer. 2012;118:2971Y2979.
4. Acute radiation morbidity scoring criteria. Radiation Therapy
Oncology Group. Available at: http://www.rtog.org/
ResearchAssociates/AdverseEventReporting/
AcuteRadiationMorbidityScoringCriteria.aspx. Accessed
July 16, 2013.
5. Nag S, Gupta N. A simple method of obtaining equivalent doses
for use in HDR brachytherapy. Int J Radiat Oncol Biol Phys.
2000;46:507Y513.
6. Gichangi P, Bwayo J, Estambale B, et al. HIV impact on acute
morbidity and pelvic tumor control following radiotherapy for
cervical cancer. Gynecol Oncol. 2006;100:405Y411.
7. McArdle O, Kigula-Mugambe JB. Unexpectedly high rates of
grade 3 and 4 acute toxicity in the treatment of cervical cancer in
sub-Saharan Africa. Gynecol Oncol. 2007;104:779Y780.
8. Shrivastava SK, Engineer R, Rajadhyaksha S, et al. HIV
infection and invasive cervical cancers, treatment with radiation
therapy: toxicity and outcome. Radiother Oncol.
2005;74:31Y35.
9. Fraunholz I, Rabeneck D, Gerstein J, et al. Concurrent
chemoradiotherapy with 5-fluorouracil and mitomycin C for
anal carcinoma: are there differences between HIV-positive and
HIV-negative patients in the era of highly active antiretroviral
therapy? Radiother Oncol. 2011;98:99Y104.
10. Hammad N, Heilbrun LK, Gupta S, et al. Squamous cell cancer
of the anal canal in HIV-infected patients receiving highly active
antiretroviral therapy a single institution experience. Am J Clin
Oncol. 2011;34:135Y139.
11. Oehler-Ja¨nne C, Huguet F, Provencher S, et al. HIV-specific
differences in outcome of squamous cell carcinoma of the anal
canal: a multicentric cohort study of HIV-positive patients
Simonds et al International Journal of Gynecological Cancer & Volume 25, Number 5, June 2015
6 * 2015 IGCS and ESGO
Copyright © 2015 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
Stellenbosch University https://scholar.sun.ac.za
receiving highly active antiretroviral therapy. J Clin Oncol.
2008;26:2550Y2557.
12. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation,
and adjuvant hysterectomy compared with radiation and
adjuvant hysterectomy for bulky stage IB cervical carcinoma.
New Engl J Med. 1999;340:1154Y1161.
13. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a
randomized trial comparing concurrent single agent cisplatin,
cisplatin-based combination chemotherapy, or hydroxyurea
during pelvic irradiation for locally advanced cervical cancer:
a Gynecologic Oncology Group Study. J Clin Oncol.
2007;25:2804Y2810.
14. Nyongesa C, Ruff P, Donde B, et al. A phase I study of
concurrent cisplatin chemotherapy in patients with carcinoma of
the cervix receiving pelvic radiotherapy. Int J Gynecol Cancer.
2006;16:1614Y1619.
International Journal of Gynecological Cancer & Volume 25, Number 5, June 2015 Chemoradiation Toxicity and HIV
* 2015 IGCS and ESGO 7
Copyright © 2015 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
Stellenbosch University https://scholar.sun.ac.za
Gynecologic Oncology 151 (2018) 215–220
Contents lists available at ScienceDirect
Gynecologic Oncology
j ourna l homepage: www.e lsev ie r .com/ locate /ygyno
Stellenbosch University https://scholar.sun.ac.zaFive-year overall survival following chemoradiation among HIV-positive
and HIV-negative patients with locally advanced cervical carcinoma in a
South African cohortHannah M. Simonds a,⁎, Matthys H. Botha b, Alfred I. Neugut c,d,e,
Frederick H. Van Der Merwe b, Judith S. Jacobson c,d
a Division of Clinical and Radiation Oncology, Department of Medical Imaging and Clinical Oncology, Stellenbosch University, Tygerberg Academic Hospital, South Africa
b Department of Obstetrics and Gynecology, Unit for Gynaecological Oncology, Stellenbosch University, Tygerberg Academic Hospital, South Africa
c Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, United States of America
d Herbert Irving Comprehensive Cancer Centre, Columbia University, New York, NY, United States of America
e Division of Oncology, Columbia University College of Physicians and Surgeons, New York, NY, United States of America
H I G H L I G H T S
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Available online 5 September 2018Objectives. In South Africa, where HIV prevalence among adults is 18.9%, cervical carcinoma is the second
most common malignancy in women. However, oncology services are considerably more accessible in South
Africa than in many neighbouring countries.
This study reports ﬁve-year overall survival in a cohort of HIV-positive and -negative cervix carcinoma patients
undergoing primary radiotherapy at a single institution in South Africa.
Methods. Prospective cohort study of all locally advanced cervix carcinoma patients referred for radiotherapy
(EBRT) from July 2007 to November 2011. Overall survival (OS) was the primary end-point.
Results. A total of 492 patients commenced treatment with radical intent, including 71 HIV-positive patients
(14.4%) and 421HIV-negative patients (85.6%). Of the 433whowere prescribed standard fractionation EBRT, 384
were prescribed concurrent platinum-based chemotherapy (88.7%). Fewer HIV-positive than HIV-negative pa-
tients (58.5% vs. 76.1%; p = 0.007) completed ≥4 cycles. The OS of HIV-negative patients was 49.5% (95%CI;
44.6%–54.4%) at 5 years. The OS of HIV-positive patients was signiﬁcantly lower, 35.9% (95% CI; 23.9%–48.0%)
at 5 years (p = 0.002). In our Cox models, factors affecting outcome were HIV infection, stage IIIB disease, pres-
ence of hydronephrosis, and delivery of concurrent chemotherapy.
Conclusion. In our large cohort, HIV-positive patients had poorer survival than HIV-negative patients, how-
ever nearly 40% survived 5 years, justifying provision of the best standard of care to HIV-positive patients with
cervical carcinoma.
© 2018 Elsevier Inc. All rights reserved.Keywords:
Cervical cancer
HIV
Chemoradiation
Radiotherapy
Survival1. Introduction
Cervical carcinoma is the second most common malignancy among
women in South Africa; the overall age-standardised incidence rate505, South Africa.(ASR) is 22.06/100,000, and among black women it is 25.90/100,000
[1]. Rates are similar in most sub-Saharan African countries and other
low- or middle-income countries (LMICs), but no high-income country
(HIC) has an ASR above 10/100,000. The LMICs also have higher cervical
carcinoma mortality rates, due in part to inadequate healthcare.
Infection with the human papilloma virus (HPV), which causes cer-
vical carcinoma, is highly prevalent in sub-Saharan Africa, and human
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Women with HIV and HPV infections are more likely than women
withHPV alone to develop persistentHPV infections, high grade cervical
intra-epithelial lesions, and ultimately cancer [3].
Since 2004, national guidelines regarding antiretroviral therapy
(ART) for HIV have been available in South Africa [4]. Until 2011, only
those patients with a CD4 b 200 cells/μl or WHO stage 4 were eligible
for ART, but current local guidelines now support commencement of
cART at a CD4 cell count b500 cells/μl [5]. In 2014, South Africa intro-
duced a school-based national HPV vaccination program for girls aged
9–10 years [6]. However, this program has yet to inﬂuence the preva-
lence of HPV in the South African population at risk for cervical cancer.
Unlike many of its neighbors, South Africa is an upper middle-
income country with large academic medical centres that can provide
cervical cancer treatment on a parwith the best practice inmanyHIC fa-
cilities. South Africa's public tertiary care hospitals have multidisciplin-
ary gynaecological oncology units and can offer LINAC (linear
accelerator) based 3-dimensional radiotherapy, high-dose rate brachy-
therapy, and chemotherapy agents.
Themanagement of cervical cancer in HIV-positivewomen has, thus
far, been based on best practice for HIV-negative women, while seeking
to optimize combination antiretroviral therapy (cART) so as tomaintain
adequate CD4 counts and to suppress the viral load [7]. Little is known
about the long-term survival of patients with cervical cancer and HIV
[8–10].
We therefore analyzed overall ﬁve-year survival in a prospective co-
hort of HIV-positive and -negative cervix carcinoma patients undergo-
ing radiotherapy, from a single institution in South Africa providing
access to high quality oncology services.2. Methods
2.1. Patient records
For this prospective cohort study, we collected a patient registry for
all cervix carcinoma patients attending for primary radiotherapy during
the timeperiod July 2007 to November 2011 in theDivision of Radiation
Oncology, Tygerberg Hospital. Patients were entered into the registry at
the start of treatment. The patients included in this analysis had stage
IB1 to stage IIIB cancers and commenced external beam radiotherapy
(EBRT) prescribed to aminimumof 40Gray (Gy)with radical intent. Pa-
tients who were excluded from the analysis were those who did not
start radiotherapy as planned and thosewhohad undergone a hysterec-
tomy, or had radical surgery for cervical cancer.Table 1
Demographic and clinical characteristics of patients with cervical carcinoma, by HIV status.
Variable HIV-negative
n = 421 (85.6%)
Median age years (interquartile range) 50 (43–58)
Age groups
39 years or less 65 (15.4%)
40–59 years 266 (63.2%)
60 years or more 90 (21.4%)
Histology
Squamous cell carcinoma 391 (92.9%)
Adenocarcinoma 15 (3.6%)
Other 15 (3.6%)
Stage
Stage IB1-IIA 12 (2.9)
IIB 120 (28.5%)
IIIA 3 (0.7%)
IIIB 286 (67.9%)
Hydronephrosis present (stage IIIB) 58 (20.3%)
Node positive (ultrasound) 67 (15.9%)
⁎ p b 0.05 regarded as signiﬁcant.Ethical approval was obtained from the University of Stellenbosch
Human Research Ethics Committee and Tygerberg Academic Hospital.
Data collected included demographic and clinical characteristics
of the patients. For HIV-positive patients, we determined whether
they had commenced cART before, or during, treatment of cervix
cancer, and we recorded their initial CD4 cell count. During the
time period of this study, viral load was not routinely tested in
the oncology clinic. Cervical cancer treatment details, including
EBRT dose, high-dose-rate (HDR) brachytherapy dose, and chemo-
therapy cycles, were documented. The total doses of EBRT and
HDR brachytherapy were calculated using equivalent dose in 2Gy
fraction (EQD2) formulas [11].
2.2. Treatment
At our institution, patients with cervix carcinoma are routinely
tested for HIV during diagnostic work-up. Many patients were diag-
nosed as HIV-positive incidentally during their work-up for suspected
cervix carcinoma. Patients who tested HIV-positive started receiving
cART either just before, or as soon as possible after commencing radia-
tion treatment. At the time of the study, cART included triple therapy
with lamivudine, efavirenz, and tenofovir, unless the creatinine clear-
ance was low, in which case the patient received stavudine instead of
tenofovir. Every HIV-positive patient commencing radiation or chemo-
radiation received concurrent cotrimoxazole prophylaxis. Because
many patients receive their routine HIV care in local clinics, we have
limited access to information on their adherence to cART therapy.
Diagnostic work-up included laboratory investigations, chest X-ray
and abdominal ultrasound. In our institution, PET-CT was not available
for the assessment of nodal and distant metastases until 2012. In addi-
tion, the evaluation of nodal cancer is challenging because HIV-
positive patients often have reactive nodes.
Patients with IB1 cancers who were not ﬁt for surgery or locally ad-
vanced IB2-IIIB disease received 45 to 52.5 Gy external beam radiation
(EBRT) in 23 to 28 fractions, 1.8–2 Gy per fraction. Patients with anae-
mia and hydronephrosis were included if they were medically ﬁt and
had adequate renal function. During the study period, the lower dose
per fraction was prescribed for HIV-positive patients or patients with
previous abdominal surgery, due to theoretical concerns regarding
gastrointestinal toxicities. Due to pressure on the radiotherapy waiting
list, some patients with stage IIIB disease, including the elderly and
those with severe medical co-morbidities, poor performance status,
or poor renal function, received a hypofractionated regimen of
40.05 Gy in 15 fractions, or 42.72 Gy in 16 fractions, and no
chemotherapy.HIV-positive Total p-Value
n = 71 (14.4%) n = 492
40 (35–49) 49 (41–57) 0.001⁎
33 (46.5%) 98 (19.9%) b0.001⁎
37 (52.1%) 303 (61.6%)
1 (1.4%) 91 (18.5%)
67 (94.4%) 458 (93.1%) 0.65
2 (2.8%) 17 (3.5%)
2 (2.8%) 17 (3.5%)
0 12 (2.4%)
15 (21.1%) 135 (27.4%)
0 3 (0.7%)
56 (78.9%) 342 (69.5%) 0.06
14 (25.0%) 72 (21.1%) 0.43
14 (19.7%) 81 (16.5%) 0.42
Table 2
Treatment characteristics by HIV status.
Variable HIV-negative HIV-positive Total p-Value
n = 421 n = 71 n = 492
Standard fractionation 369 (87.6%) 64 (90.1%) 433 (88.0%) 0.55
Hypofractionation 52 (12.4%) 7 (9.9%) 59 (12.0%)
Median EQD2 Gy (interquartile range) 77.7 Gy
(75.0–80.8)
76.3 Gy
(69.3–81.5)
77.7 Gy
(75.0–80.9)
0.94
≥69.25 Gy EQD2 total dose 356 (84.6%) 54 (74.1%) 410 (83.3%) 0.08
≥20 Gy HDRa 333 (90.3%) 51 (79.7%) 384 (88.5%) 0.02⁎
Chemo 4 or more cyclesb 252 (76.1%) 31 (58.5%) 283 (73.7%) 0.007⁎
1–3 cycles 79 (23.9%) 22 (41.5%) 101 (26.4%)
Transfusion givenc 173 (42.3%) 45 (66.2%) 218 (45.7%) b0.001⁎
a If prescribed 1.8–2 Gy per fraction (n = 433).
b If prescribed 1.8–2 Gy per fraction and chemotherapy (n = 384).
c Missing data 15 patients.
⁎ p b 0.05 signiﬁcant.
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[12]. We used conformal 3-dimensional planning and a 6–18 MV
(megavoltage) energy, 4-ﬁeld arrangement. We then delivered 20 to
26 Gy Ir193 HDR intracavitary brachytherapy in 4 to 5 fractions. During
the timeperiod of this study, no image-guided brachytherapywas avail-
able. The absoluteminimum total dose considered adequate for the pur-
pose of this study was 69.25 Gy EQD2 (45 Gy EBRT and 20 Gy in 4
fractionsHDR brachytherapy). After 2009,we increased the brachyther-
apy dose to 25Gy in 5 fractions in keeping with international recom-
mendations that total dose EQD2 should be N80 Gy [13] (Higher doses
per fraction are not suitable for the straight source HDR technique).
Treatment is scheduled to be completed within 55 days.
Most patients also received cisplatin 40 mg/m2 weekly, but if their
calculated glomerular ﬁltration rate or ethylenediaminetetraacetic
acid (EDTA) glomerular ﬁltration rate was b50 ml/min, they received
carboplatin area-under-the-curve 2 (AUC2) weekly. We did not modify
the dose for patients with a low CD4 cell count unless it fell below 200,
in which case chemotherapy was omitted. Patients whose haemaglobin
(Hb) fell below 10 g/dl received a red cell concentrate transfusion
(resource constraints limit the use of blood transfusions).
2.3. Follow-up
Follow-up is scheduled routinely at 6 weeks post treatment, every
three months in year 1, every six months in years 2 to 5, and annually
to 10 years. Due to the poor socio-economic situation of many patients,
and the distance theymust travel fromhome to the cancer centre, manyFig. 1. 5-Year overall surdo not adhere to the follow-up program. Consequently, we could not
determine local recurrence rates and progression- or disease-free sur-
vival at ﬁve years. Therefore, the primary end-point of this study was
overall survival, measured from the start of EBRT to date of death or
last recorded visit. Patient data were censored on 1 December 2016,
5 years after the last patient commenced EBRT in the cohort. We ob-
tainedmortality data from the South AfricanMedical Research Council's
national population register (NPR), which can provide a date of death
for those patients who have a national identity number. We right-
censored thosewithout a national identity number at their last recorded
date of follow-up. For most patients, we could not establish cause of
death because we lacked access to death certiﬁcate information; we
had in-patient records of pre-terminal events for only a few patients.
For the purposes of this study, therefore, we analyzed all-cause mortal-
ity or overall survival.
2.4. Statistics
We evaluated the statistical signiﬁcance of differences in demo-
graphic factors and clinical parameters between HIV-positive and HIV-
negative patients by means of t-tests for continuous variables and χ2
tests for categorical variables. Overall survival was computed using the
Kaplan-Meier method. We developed Cox multivariable logistic regres-
sion models for the associations of HIV status, stage, total dose of radia-
tion, and prescription of chemotherapy with mortality, expressing
results as hazard ratios (HRs) with 95% conﬁdence intervals (CIs). All
tests were 2-sided, and p values of 0.05 or less were consideredvival by HIV status.
Table 3
Predictors of all-cause mortality.
Variable Hazard ratio 95% CI p-Value
HIV status
Negative Referent
Positive 1.45 1.01–2.08 0.04⁎
Stage
IB1-IIIA Referent
IIIB 1.50 1.10–2.05 0.01⁎
Hydronephrosis
Absent Referent
Present 1.70 1.12–2.59 0.01⁎
Total EQD2 dose
N69.25 Gy Referent
b69.25 1.01 0.65–1.57 0.96
Chemotherapy
≥4 cycles Referent
1–3 1.18 0.84–1.65 0.34
0 1.86 1.26–2.76 0.02⁎
⁎ p b 0.05
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gram (version 25.0; SPSS, Inc., Chicago, IL).3. Results
FromMay 2007 to November 2011, 525 cervical carcinoma patients
stage IB1 to IIIB commenced primary radiotherapy treatment. Of these,
33 patients received palliative treatment of 8–30 Gy and were excluded
from this analysis. The remaining 492 patients were prescribed N40 Gy
EBRT and were included.3.1. Demographic and clinical characteristics
The cohort included 71 HIV-positive patients (14.4%) and 421 HIV-
negative patients (85.6%) (Table 1). Their median age was 49 years,
but the HIV positive group was younger at 40 years than the HIV-
negative group at 50 years (p = 0.001). Most of the patients (69.5%)
were diagnosed in stage IIIB, 78.9% of theHIV group and 67.9% of the un-
infected group (p = 0.06). The vast majority of cases were pathologi-
cally deﬁned as squamous cell carcinoma (93.1%).
Among the HIV infected patients, the median CD4 count was
386 cells/μl (iQR 256–450); 43 (60.6%) of the HIV-infected patients
were on cART at the time of cervical cancer diagnosis, with a median
CD4 of 366 cells/μl (iQR 276–458). The remaining 28 patients com-
menced treatment before or during EBRT, with a median CD4 of
324 cells/μl (iQR 209–407). Eleven patients had a recorded CD4 b 200,
7 of whom were not on cART.3.2. Treatment parameters
Overall, 433 (88.0%) patients (87.6% of HIV-positive and 90.1% of
HIV-negative patients) were prescribed standard fractionation EBRT
(Table 2).
The median EQD2 to point A was 77.7 Gy (iQR 75.0–80.9), for both
groups. A large proportion of the cohort received a minimum of
69.25 Gy (83.3%); more of the HIV-negative patients (84.6%) than the
HIV-positive patients (74.1%) completed the total prescribed radiother-
apy (p=0.08). Of thosewhowere prescribed 1.8–2Gy per fraction, 90%
of the HIV-negative patients but only 80% of the HIV-positive patients
completed brachytherapy (p = 0.012).
Of the 433 patients in the standard fractionation group, 384 (88.7%)
were prescribed platinum-based chemotherapy. Fewer HIV-positive
than -negative patients were able to complete 4 ormore cycles. In addi-
tion,more HIV-positive than -negative patients required a red blood cell
transfusion to maintain a hemoglobin over 10 g/dl, 66.2% (p b 0.001).3.3. Survival
The median follow-up for the 492-patient cohort was 30.5 months
(0–114 months) and 22,367 person-months. Two-year and ﬁve-year
survival data were not available for 35 (7.1%) and 44 (8.9%) of the
total cohort, respectively. The overall survival for the whole cohort
was 59.1% (median not reached) at 2 years and 47.6% (median,
4.2 years; 95%CI, 27.1–72.9 months) at 5 years. Among patients who
were prescribed chemoradiation and completed at least one cycle, the
OS was 51.8% at 5 years.
HIV-negative patients had an OS of 62.0% (95%CI; 57.2%–66.7%) at
2 years and 49.2% (95%CI; 44.6%–54.4%) at 5 years. HIV-positive patients
had poorer OS, 41.6% (95%CI; 29.5%–53.7%) at 2 years and 35.9% (95%CI;
23.9%–48.0%), at 5 years (p= 0.002) (Fig. 1).Within two years, 38 HIV-
positive patients had died; only three more patients died in the next
three years. The difference in survival remained signiﬁcant when pa-
tients with a CD4 cell count of 200 or less were excluded from the anal-
ysis. Within the HIV-positive cohort, 5-year OS of those established on
cART was similar to that of patients newly diagnosed with HIV, 38.4%
vs. 31.4% (p = 0.322). The difference between the 5-year survival of
the HIV negative group and that of HIV-positive patients established
on cART was not quite statistically signiﬁcant, 49.5% vs. 38.4% (p =
0.063).
The two- and ﬁve-year survival for Stage IB1-IIIA patients was 74.3%
and 61.5% overall. For the Stage IIIB patients, 2- and 5-year OSwas 52.2%
and 41.3% overall. Survival was signiﬁcantly lower for HIV-positive pa-
tients (Supplementary Table 1, S1).
In bivariate analysis, survival was not inﬂuenced by age, nodal sta-
tus, histological subtype or transfusion status. The presence of
hydronephrosis did, however, impact survival signiﬁcantly.
With respect to total radiotherapy dose delivered, those who re-
ceived 69.25 Gy EQD2 or more fared better, with a 5-year OS of 50% vs.
36.9% (p = 0.002). HIV-status again conferred a lower OS even on
those receiving adequate radiation (Supplementary Table 1).
In the standard fractionation cohort, survival was strongly associ-
ated with chemotherapy but was adversely affected by HIV-positivity.
Among patients who received 4 or more cycles of platinum chemother-
apy and complete radiotherapy N69.25 GY, 5-year OS was signiﬁcantly
better in the HIV-negative patients at 57.0% [Stage IB1-IIIA 71.9%; IIIb
48.2%] than at 35.2% in the HIV-positive patients [Stage IB1-IIIA 66.8%;
IIIB 25.2%] (p = 0.009).
Those who received no chemotherapy, due to their comorbidities
and poor performance status, fared worst of all; 5-year OS was 36.2%
and 20.2% in the HIV-negative and -positive patients, respectively.
We developed Cox regression models for the 433 patients who had
been deemed ﬁt for radical standard fractionation radiotherapy, with
or without chemotherapy (Table 3). The models included all factors
found to be signiﬁcant on bivariate analysis: stage at diagnosis, HIV sta-
tus, presence of hydronephrosis, completion of EQD2 69.25 Gy radio-
therapy and any chemotherapy. Red cell transfusion status was not
associated with poor survival. Factors that were signiﬁcantly associated
with poor overall survival were HIV infection, Stage IIIB disease, the
presence of hydronephrosis and ineligibility for chemotherapy.
4. Discussion
This study is one of the ﬁrst to report the 5-year overall survival of a
prospective cohort of HIV-positive cervical carcinoma patients. The
overall 5-year survival of the 492 patients in the cohort, including pa-
tients with risk factors that are frequently reasons for exclusion from
clinical trials, such as HIV infection and hydronephrosis, was 47.8%. De-
mographic and clinical factors adversely affecting outcome in the 433
patients treated with standard fractionation external beam radiother-
apywere HIV positivity, advanced stage (stage IIIB) disease, and, in par-
ticular, hydronephrosis. Thosewhowere unﬁt to receive chemotherapy
fared worse.
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apy and brachytherapy was high; N80% received the prescribed mini-
mum dose. In addition, 76% of the HIV-negative patients were able to
tolerate at least 4 cycles of the prescribed concomitant platinum-
based chemotherapy.
HIV-positive patients were less likely than HIV-negative patients to
complete prescribed radiotherapy and even less likely to complete che-
motherapy. However, approximately 75% of HIV-positive patients re-
ceived adequate radiotherapy, and 58% completed the prescribed
minimum cycles of chemotherapy.
In this observational study, patients who were not prescribed che-
motherapy or were prescribed hypofractionated regimens were more
likely than others to have a poor performance status, inadequate renal
function, or other co-morbidities, such as active tuberculosis, which is
common in the Western Cape Province of South Africa.
In a subset of HIV-negative patients without hydronephrosis, who
completed chemoradiation, the 5-year overall survival was 58.4% (stage
IIB 71.9% and stage IIIB 49.7%). These results are similar to those of a re-
cent chemoradiation trial from Tata Memorial Hospital in India, with ar-
guably a comparable, though highly selected, treatment population [14].
The 1243-patient United Kingdom audit of outcomes for chemoradiation
reported a 5-year OS of 55% for the chemoradiation group, 61% for stage
IIB and 44% for the stage IIIB patients [15]. Overall survival among our
HIV-negative patients who were prescribed chemoradiation was there-
fore consistent with both developing and developed world data.
We could ﬁnd no other prospective cohort study reporting 5-year
survival for an HIV-positive cohort with an HIV-negative comparison
group and complete demographic and treatment data. Coghill et al. re-
ported on associations between HIV status and cancer deaths based on
cancer registry data in the United States [8]. Among cervix carcinoma
patients in the period 1996–2010, those who were HIV-positive had
an all-cause mortality hazard ratio of 2.50, but a cancer-speciﬁc hazard
ratio of 1.27 that was not statistically signiﬁcant. In our sample, we
could not tell whether the deaths we identiﬁed were AIDS-related or
cancer-speciﬁc because we receive only limited death notice informa-
tion. Most of the HIV-positive patients who died in our study did so
within the ﬁrst 2 years after diagnosis. We can speculate that HIV
makes cervical carcinoma more biologically aggressive than it would
otherwise be, or that cancer therapy adversely affects HIV control.
With inadequate clinical follow-up, it is unclear which scenario is
more likely.
Two HIV-positive cohort studies from Botswana, Dryden-Petersen
et al. and Grover et al., presented conﬂicting results at their 2-year
follow-up point [16,17]. In the former, HIV infection nearly doubled
the risk of death (HR 1.95, 95% CI 1.2–3.17; p = 0.007), and median
overall survival was 21.7 months. In the latter, the HR 1.12 was not sta-
tistically signiﬁcant, themedian OSwas not reported, and the 2-year OS
was 66% amongHIV-positive patients, N20%higher than that of our HIV-
positive patients. The differences between the two Botswana studies,
noted by Grover et al., were partially explained by the inclusion of pa-
tients who were prescribed only palliative care in the Dryden-
Petersen cohort, a lower CD4 cell count, and missing treatment data.
In our unit, unlike that in the two Botswana studies, very few patients
with early-stage disease are treated with chemoradiation. At our insti-
tution, gynaecological oncology surgeons manage active screen-and-
treat programs and provide radical surgery for all early-stage disease.
The patient population in our unit probably consists mainly of women
who did not access the screening program. As a result, most of them
present with locally advanced disease; nearly 80% of the HIV-positive
patients in our study sample were stage IIIB, potentially accounting for
the low survival of the cohort as a whole. In addition, our HIV-positive
patients had a lower median CD4 cell count than those in the Grover
study, probably because many of them were referred in the era prior
to universal cART coverage.
Ferreira et al. performed a matched retrospective cohort study of all
cervix cancer patients treated at a single institution in Brazil over a 12-year period [9]. The cohort included 87 HIV-positive patients. Of the
subset who underwent radiotherapy, the HIV-positive patients were
more likely to relapse within 2 years.
In a study of outcomes among 228 stage IIB patients, 13 of whom
were HIV-positive, in South Africa, Jemu et al. found that HIV infection
did not affect survival [18]. In Ethiopia, a cohort study of 1655 cervix
cancer patients, of whom 139 were HIV-positive, also found that HIV
status did not impact survival [10]. However, 789 patients were listed
as HIV status unknown, and the study did not categorize patients by
therapy received, although it noted that 71% of patients who received
radiotherapy were treated with palliative intent. Finally a small
matched cohort study of 50 HIV-positive patients undergoing adjuvant,
radical and palliative radiotherapy in South Africa found that HIV infec-
tion adversely affected the ability to complete treatment and led to poor
overall survival [19].
The strengths of our study include the prospective collection of de-
mographic and treatment data. Although a number of patients were
lost to clinical follow-up, access to the national registry ensured that
vital status was available for over 90% of the cohort at 5 years. All pa-
tients were managed within a multi-disciplinary team environment,
and high quality oncological and infectious disease interventions were
available at no or minimal cost to the patients. Our sample included
only patients treated with primary radiotherapy with curative intent.
Adherence to planned radiotherapy was 98%, as we noted in our previ-
ous paper [12]. Most patients who failed to complete radiotherapy did
so because of medical complications.
Limitations of the study include the use of paper records prior to the
introduction of an electronic patient management system in radiother-
apy; as a result, some subjects may have been missed. Information on
acute toxicity was not reported in this study because it was available
only for a subset of the cohort and had been previous reported [20].
Lack of data on late toxicity, local recurrence, distant metastases and
cause of death is a limitation but one that is common among survival
studies conducted in low resource settings, where many patients ﬁnd
it difﬁcult to attend for frequent follow-up. The proportion of HIV-
positive patients in our sample was 14.4%, relatively low compared to
that of other centres in sub-Saharan Africa, but consistent with HIV
prevalence in our institution's catchment area. The HIV-positive pa-
tients in our sample had a moderately lowmedian CD4 count, probably
because many of our patients were diagnosed and treated prior to the
full cART rollout. A new cohort study in the ‘modern’ era is needed to
see if cervical cancer patients whose HIV is well controlled have better
survival than the HIV-positive patients in this study. Finally, our cohort
included both patients who were deemed ﬁt for radical therapy and
patients who had co-morbidities that limited prescription of
chemotherapy.5. Conclusions
This cohort study of nearly 500 patients with locally advanced cervi-
cal cancer found that among women eligible for curative treatment for
cervical cancer, HIV-positive patients had poorer overall survival than
HIV-negative patients. Additional factors affecting outcome were cervi-
cal cancer stage and concurrent chemotherapy. A number of HIV-
infected patients were able to tolerate adequate chemoradiation
(58.5%), or radiation alone (74.1%), and nearly 40% were alive at
5 years. The outcomes of the HIV-negative cohort were comparable to
data from the developed world. Despite their lower survival, we con-
clude that HIV-positive patients should be provided access to antiretro-
viral therapy, an effective screening program, and the best standard of
care both in surgical and non-surgical oncology therapy in order to op-
timize outcomes. In addition, including HIV-positive patients in clinical
trials will assist in answering questions that cohort studies cannot.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2018.08.038.
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Highlights
•	 More than 80% of patients had pelvic nodal involvement, and more than 40% had uptake in common iliac and/or pa-
ra-aortic nodes.
•	 Overall, 84.5% were upstaged after PET-CT scan and it was not associated with HIV status.
•	 HIV status did not have an impact on PET-CT findings or oncology treatment decisions.
AbsTrACT
Introduction Positron emission tomography-computed 
tomography (PET-CT) imaging is commonly used to 
identify nodal involvement in locally advanced cervical 
carcinoma, but its appropriateness for that purpose among 
HIV-positive patients has rarely been studied. We analyzed 
PET-CT findings and subsequent treatment prescribed in 
patients with locally advanced cervical carcinoma in Cape 
Town, South Africa.
Methods We identified a cohort of consecutive cervical 
carcinoma patients International Federation of Gynecology 
and Obstetrics (FIGO) stage IIB to IIIB at our cancer center 
who underwent a planning 18-fluorodeoxyglucose (18FDG) 
PET-CT scan from January 2015 through December 2018. 
Demographics, PET-CT findings, and subsequent treatment 
prescribed were recorded. Patients were selected for 
PET-CT only if they had no signs of distant disease on 
staging chest X-ray or abdominal ultrasound; were 
deemed suitable for radical chemoradiation by the multi-
disciplinary team; and had normal renal function. HIV-
positive patients ideally had to have been established on 
continuous antiviral therapy for more than 3 months and to 
have a CD4 cell count above 150 cells/μL. Small cell and 
neuroendocrine carcinoma cases were excluded from the 
study. Differences in demographic and clinical measures 
between HIV-positive and HIV-negative patients were 
evaluated by means of t-tests for continuous variables and 
χ2 tests for categorical variables.
results Over a 4 year period, 278 patients—192 HIV-
negative (69.1%) and 86 HIV-positive (30.9%)—met the 
inclusion criteria. HIV-positive patients had a median CD4 
count of 475 cells/µL (IQR 307–612 cells/µL). More than 
80% of patients had pelvic nodal involvement, and more 
than 40% had uptake in common iliac and/or para-aortic 
nodes. Nodal involvement was not associated with HIV 
status. Fifty-four patients (19.4%) had at least one site of 
distant metastatic disease. Overall, 235 patients (84.5%) 
were upstaged following PET-CT staging scan. Upstaging 
was not associated with HIV status (HIV-negative 83.9% 
vs HIV-positive 87.2%; p=0.47). Ten patients who did not 
return for radiotherapy were excluded from the analysis. 
Following their PET-CT scan, treatment intent changed for 
124 patients (46.3%): 53.6% of HIV-positive patients and 
42.9% of HIV-negative patients (p=0.11).
Conclusion We found no differences between HIV-
positive or HIV-negative patients in nodal involvement or 
occult metastases, and PET-CT imaging did not lead to, 
or justify, treatment differences between the two groups. 
Future studies will evaluate survival and correlation of 
upstaging with outcome.
InTroduCTIon
Cervical carcinoma is one of the most frequently 
diagnosed malignancies in women throughout 
sub-Saharan Africa. In South Africa, its age-stand-
ardized incidence rate is >40 per 100 000 women; 
in 2018, more than 12 000 women were diagnosed 
with invasive cervical cancer.1 2 In addition, cervical 
carcinoma is associated with HIV, and in South Africa 
HIV prevalence is 26.3% among women aged 15–49 
years.3 Various imaging modalities (eg, chest X-ray, 
abdominal ultrasound) are used to determine the 
extent of disease in cancer patients. In higher-income 
countries, newer technologies, such as magnetic 
resonance imaging and positron emission tomogra-
phy-computed tomography (PET-CT) scanning, are 
often used for this purpose. The latter has proved 
to be highly effective in identifying poor prognostic 
features of cervical carcinoma, such as positive pelvic 
lymph nodes, and in accurately defining targeted 
treatment by radiation.4 5 The addition of PET-CT to 
the staging algorithm has changed treatment intent 
and enhanced the accuracy of radiotherapy planning. 
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Table 1 Patient demographics and clinical characteristics by HIV status
HIV-positive HIV-negative Whole cohort P value
86 (30.9%) 192 (69.1%) 278
Age (median) 41 years (26–67 years)
SD 8.75
50 years (26–79 years)
SD 11.77
47 years (26–79 years) 0.00*
Histology† 0.65
  Squamous cell 81 (96.4%) 178 (92.7%) 259 (93.8%)
  Other 3 (3.6%) 14 (6.3%) 17 (6.2%)
FIGO stage 0.46
  IIB 15 (17.4%) 29 (15.1%) 44 (15.8%)
  IIIA 0 3 (1.6%) 3 (1.1%)
  IIIB 71 (82.6%) 160 (83.3%) 231 (83.1%)
*P<0.05 considered significant.
†Complete data for 84 out of 86 HIV-positive patients.
FIGO, International Federation of Gynecology and Obstetrics.
PET-CT is now increasingly available in middle-income countries, 
including South Africa. A small study found that PET-CT led to 
conversion to palliative regimens or the addition of extended field 
irradiation for involved para-aortic nodes in more than 35% of 
patients.6
The 2018 update to the International Federation of Gynecology 
and Obstetrics (FIGO) staging of cervical cancer has highlighted 
the need for accurate imaging of nodal involvement.7 Patients with 
evidence of nodal disease must be upstaged to IIIC1r for pelvic 
or IIIC2r for para-aortic nodal disease. HIV-positive patients who 
undergo PET-CT imaging may have fluorine-18 fluorodeoxyglucose 
(18FDG)-avid benign pathology, such as reactive lymphadenopathy 
or co-existent tuberculosis. This limitation in specificity may lead 
to some uncertainty in interpretation of abnormal findings and 
thus raises questions about the suitability of 18FDG PET-CT staging 
for HIV-infected patients with cervical carcinoma. We therefore 
conducted a study of the contribution of PET-CT to staging and 
stratification for treatment in HIV-negative and HIV-positive women 
in a large cohort of patients with cervical cancer. Our hypothesis 
was that nodal involvement, as determined on PET-CT, would be 
more prevalent in HIV-positive than in HIV-negative patients due to 
a greater proportion of false positives in the former group; and that 
PET-CT findings among HIV-positive patients would lead to inappro-
priate changes in radiotherapy fields or treatment intent.
METHods
This retrospective/prospective cohort study was undertaken at 
Tygerberg Academic Hospital, in Cape Town, South Africa. Study 
participants were consecutive HIV-positive and HIV-negative 
patients diagnosed with locally advanced cervical carcinoma (FIGO 
stage IIB-IIIB) who underwent a staging PET-CT scan from January 
2015 through December 2018. Ethical approval was obtained from 
the University of Stellenbosch Human Research Ethics Committee 
(S17/01/016). For the retrospective cohort (January 2015 through 
February 2017) patients were identified through the Nuclear 
Medicine booking system. For the prospective cohort (March 
2017 through December 2018), patients were consented at their 
new-patient visit to Radiation Oncology and referred to Nuclear 
Medicine as per routine clinical practice.
For the 12 gynecology oncology patients scheduled per week 
for radiotherapy, only 3–5 PET-CT planning scan appointments 
were available. Patients were selected for PET-CT only if they had 
advanced stage IIB, IIIA or IIIB disease with no signs of distant 
disease on staging chest X-ray or abdominal ultrasound; were 
deemed suitable for radical chemoradiation by the multi-disci-
plinary team; and had normal renal function. HIV-positive patients 
ideally had to have been established on continuous antiviral therapy 
for more than 3 months and to have a CD4 cell count above 150 
cell/μL. Small cell and neuroendocrine carcinoma cases were 
excluded from the study.
Patients fasted for at least 4 hours before administration of the 
radiopharmaceutical. The PET-CT scans were performed using a 
Phillips Gemini Big Bore time-of-flight 16-slice PET/CT camera 
(Philips Medical Systems, Best, The Netherlands) with a flat couch 
top suitable for radiotherapy planning. The systems were calibrated 
according to the European Association of Nuclear Medicine Research 
Ltd standards. Patients were imaged from base of skull to mid-thigh 
in the supine position with a low-dose CT and PET scan. A second, 
contrast-enhanced planning CT scan from the pelvic area up to T10 
was exported to the radiation oncology planning system for volume 
delineation. The PET and low-dose CT images were evaluated and 
reported jointly by an experienced team that included a nuclear medi-
cine physician and a radiologist. Lymph nodes were interpreted as 
inflammatory when located in nodal basins not draining the primary 
tumor (directly or indirectly), and when the nodes appeared symmet-
rical in distribution and were sub-centimeter with only mild uptake. 
Lymph nodes were interpreted as malignant when enlarged and 
demonstrating moderate or intense uptake well above the degree 
of uptake in presumed inflammatory nodes. Avidity in nodes similar 
to the primary lesion was reported as malignant. Complex cases 
were discussed with the radiation oncologist when clarification was 
needed. Equivocal or ill-defined lesions on the PET-CT were high-
lighted as suspicious, and further investigations were left to the clini-
cian’s discretion (capacity to biopsy suspicious lesions was limited 
because of long surgical and diagnostic radiology waiting lists).
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Table 2 PET-CT findings by HIV status
HIV-positive
N=86
HIV-negative
N=192
All
N=278 P value
Positive nodes (any) 75 (87.2%) 159 (82.8%) 234 (84.2%) 0.35
  Pelvic 73 (84.9%) 150 (78.1%) 223 (80.2%)
  Common iliac 45 (52.3%) 85 (44.3%) 130 (46.8%)
  Para-aortic 38 (44.2%) 74 (38.5%) 112 (40.3%)
  Distant 12 (14%) 18 (9.4%) 30 (10.8%)
Lung 12 (14%) 22 (11.5%) 34 (12.2%) 0.56
Liver 0 3 (1.6%) 3 (1.1%) 0.24
Bone 1 (1.2%) 6 (3.1%) 7 (2.5%) 0.33
Other 1 (1.2%) 2 (1.0%) 3 (1.1%) 0.93
CT, computed tomography; PET, positron emission tomography.
Original data, including demographic and clinical character-
istics, were extracted from the patients’ folders. Reports and 
images were retrieved from the Nuclear Medicine database 
(Hermes Medical Solutions, Stockholm, Sweden). Radiotherapy 
data were retrieved from the MOSAIQ patient management 
system. PET-CT reports were coded for involved pelvic nodes, 
common iliac nodes, para-aortic nodes, distant nodal disease, 
and metastases to lung, liver, bone, and other sites. Equivocal or 
unrelated clinical findings were noted. Following introduction of 
the revised FIGO 2018 staging system, patients were allocated to 
stage IIB, IIIA, IIIB, IIIC1r, IIIC2r, or IVB based on clinical examina-
tion and the PET-CT findings.
All locally advanced cervical carcinomas deemed fit for treatment 
received 46–50.4 Gy in 23–28 fractions external beam radiotherapy 
(EBRT) to primary disease, parametria, upper vagina, and pelvic 
node groups up to and including the common iliac nodes. Forty-five 
Gray (45 Gy) in 25 fractions to a para-aortic node field extending 
to the renal hilum was prescribed for involved para-aortic node or 
upper common iliac nodes at the clinician’s discretion. Prophylactic 
para-aortic node radiotherapy was not performed for positive nodes 
if all were below the common iliac vessels. EBRT was delivered 
concurrently with cisplatin 40 mg/m2 up to five cycles, if renal func-
tion allowed, and was followed by high dose-rate brachytherapy 
22–25 Gy in 4–5 fractions. During the period of this cohort, inten-
sity-modulated radiotherapy to boost involved nodes was not in 
use; EBRT was delivered using 3D conformal techniques. Patients 
unsuited for radical radiotherapy were prescribed hypofractionated 
EBRT 40.05 Gy in 15 fractions with or without brachytherapy. Palli-
ative patients received 10 Gy in a single fraction, repeated monthly 
to three fractions in selected cases, and/or palliative chemo-
therapy. Additional factors considered before starting treatment 
included deterioration in performance status and new-onset renal 
dysfunction.
Differences in demographic and clinical measures between 
HIV-positive and HIV-negative patients were evaluated by means 
of t-tests for continuous variables and χ2 tests for categorical vari-
ables. All tests were two-sided, and values of p≤0.05 were consid-
ered significant. Data were analyzed using the Statistical Package 
for the Social Sciences (SPSS) statistics software program (version 
25.0; SPSS, Inc, Chicago, IL).
rEsulTs
In the 4 year study period, 1093 patients with cervical carcinoma, 
including all radical, adjuvant, and palliative patients registered on 
MOSAIQ, were referred for radiation therapy. Of these patients, 278 
met the inclusion criteria and were included in the final analysis 
(Table  1). The study included 192 HIV-negative patients (69.1%) 
and 86 HIV-positive patients (30.9%) (Table 1). The median age was 
47 years (range 26–79). The HIV-positive patients were significantly 
younger than the HIV-negative patients (p<0.001) with a median 
CD4 count of 475 cells/µL (IQR 307–612 cells/µL). Viral load was 
available for 79 of 86 patients with a median of 0 copies/mL (IQR 
0–100 copies/mL); 91.1% (n=72) had <1000 copies/mL as per 
WHO guidelines for viral suppression.8 Most patients had squamous 
cell carcinomas and were clinically staged FIGO IIIB before their 
PET-CT imaging.
PET-CT findings
More than 80% of patients had pelvic nodal involvement, and 
more than 40% had uptake in common iliac and/or para-aortic 
nodes (Table  2). Nodal involvement was not associated with HIV 
status. Fifty-four patients had at least one site of distant meta-
static disease, including lung (n=34), nodes (n=30), bone (n=7), 
liver (n=3), and sacral nerve (n=3) (Figure 1). Overall, 235 patients 
(84.5%) were upstaged to FIGO (2018) IIIC1r (37.4%), IIIC2r (27.7%) 
or IVB (19.4%) after PET-CT staging scan (Table 3). Upstaging was 
not associated with HIV status (HIV-negative 83.9% vs HIV-posi-
tive 87.2%; p=0.47). More than two-thirds of the patients also had 
benign or unrelated pathology (n=191; 68.7%), mainly post-in-
flammatory lung nodules. Other findings included active respira-
tory infections, bone marrow hyperplasia secondary to anemia, and 
undiagnosed breast cancer. These findings were unrelated to HIV 
status (HIV-negative 67% vs HIV-positive 73.3%; p=0.27). HIV-re-
lated lymphadenopathy was identified in 20 patients.
Treatment intent after PET-CT
Among the 268 patients who returned for treatment after the 
PET-CT planning scan, the intent of treatment changed from radical 
chemoradiation to hypofractionated EBRT in 27 (10.1%) patients, 
and to palliative EBRT in 32 (11.9%) (Table 4). Radical radiation was 
altered to include extended field para-aortic node EBRT in 65 cases 
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Figure 1 PET-CT images of a 63-year-old woman, initial stage IIIB squamous cell carcinoma of the cervix, HIV negative. 
Imaging findings included nodal uptake, lung metastases, and infiltration of the right sacral nerve. The patient received 
palliative pelvic radiotherapy and was started on palliative chemotherapy. CT, computed tomography; PET, positron emission 
tomography.
Table 3 Final FIGO stage (2018) by HIV status
HIV-positive
N=86
HIV-negative
N=192
All
N=278 P value
IIB 2 (2.3%) 7 (3.6%) 9 (3.2%) 0.34
IIIA 0 2 (1.0%) 2 (0.7%)
IIIB 10 (11.6%) 22 (11.5%) 32 (11.5%)
IIIC1r 28 (32.6%) 76 (39.6%) 104 (37.4%)
IIIC2r 25 (29.1%) 52 (27.1%) 77 (27.7%)
IVB 21 (24.4%) 33 (17.2%) 54 (19.4%)
FIGO, International Federation of Gynecology and Obstetrics.
(24.3%). Following the PET-CT, overall treatment intent changed in 
124 patients (46.3%), 53.6% in HIV-positive patients and 42.9% 
in the HIV-negative patients (p=0.11) (online supplementary figure 
1). Of the 104 patients upstaged to IIIC1r, 95 (91.3%) proceeded to 
standard fractionation radiotherapy. Of the 77 patients upstaged 
to IIIC2r, 67 (87.0%) underwent EBRT. Para-aortic nodal extend-
ed-field radiotherapy was prescribed to 31.1% (n=65) of cases, 
including 75% (n=48) of the IIIC2r patients and 11.8% (n=11) of 
the IIIC1r patients, all of whom had common iliac nodal uptake 
on PET-CT. None of the patients staged IIB, IIIA or IIIB on PET-CT 
received extended field EBRT. Of the 54 patients upstaged to IVB 
disease, 13 were still prescribed radical EBRT (including six who 
received extended-field EBRT) after multi-disciplinary review of the 
images by the oncologist and nuclear medicine team.
dIsCussIon
Most of the 278 patients in our study had nodal disease, and nearly 
half had a change in treatment after PET-CT. Integrating PET-CT into 
the staging algorithm upstaged 85% of patients overall, including 
65.1% upstaged to the current FIGO 2018 groups of IIIC1r or IIIC2r 
following findings of pelvic and/or para-aortic nodal involvement. 
The remaining 20% were diagnosed with distant metastatic 
disease, which in some cases was isolated (oligometastatic). The 
HIV-positive patients included in this cohort were immune-compe-
tent, with a high median CD4 count, and more than 90% were virally 
suppressed. Baseline clinical stage (before PET-CT) was not asso-
ciated with HIV status. HIV status was not associated with differing 
PET-CT findings for either nodal disease or distant metastases.
In a recent study in South Africa, Id et al found that 36.4% of 126 
patients with cervical carcinoma (including 74 with HIV and 88 with 
stage IIb or IIIB disease) had positive nodal involvement on PET-CT.9 
Stage was not associated with HIV status. In our cohort, more 
patients had positive nodes, most probably due to more advanced 
disease. Because the HIV-positive patients included in our cohort 
were immune-competent, our findings may not be generalizable 
to patients with a high HIV viral load.10 Other recent studies have 
found no difference in stage distribution between HIV-negative and 
HIV-positive patients with malignancy. Mhlanga et al compared 
HIV-positive lymphoma patients to a control group without malig-
nancy and found that the best way of distinguishing them was 
through asymmetry and quantitative measures of intensity of 18FDG 
uptake (higher scores in malignant nodes)—methods similar to 
those used in our institution.11 In a South African retrospective 
cohort of patients with Hodgkin’s lymphoma, Lawal et al found no 
significant difference between those with and those without HIV in 
PET-CT findings and metabolic indicators.12
The accuracy of PET-CT in detecting nodal metastases in 
patients with locally advanced disease is difficult to determine with 
absolute certainty; in most clinical settings, such nodes are unlikely 
to be sampled to confirm involvement. The prevalence of pelvic 
and/or para-aortic node positivity on PET-CT was higher among 
our patients (both HIV-positive and HIV-negative) than has been 
reported in international data on HIV-negative populations. In the 
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Table 4 Treatment intent by HIV status
HIV-positive
N=84
HIV-negative
N=184
All
N=268* P value
Standard fractionation EBRT 39 (46.4%) 105 (57.1%) 144 (53.7%) 0.11
Extended field EBRT 24 (28.6%) 41 (22.3%) 65 (24.3%)
Hypofractionated EBRT 12 (14.3%) 15 (8.2%) 27 (10.1%)
Palliative EBRT 9 (10.7%) 23 (12.5%) 32 (11.9%)
*Exclusion of 10 patients who did not return for treatment.
EBRT, external beam radiotherapy.
recent EMBRACE trial, of more than 1000 cervical cancer patients, 
52% had positive nodes on imaging.13 That study included patients 
with earlier-stage disease and thus lower risk of nodal metastases. 
Similarly, a large PET-CT study undertaken by Kidd et al found posi-
tive nodal uptake in 58% of squamous cell carcinomas, a smaller 
proportion than in our cohort.14 In a second study by Kidd et al, only 
32% of patients with stage IIIB disease had positive nodes.15 Our 
study population was a selected high-risk group in that most had 
stage III disease, most likely due to more delayed access to health-
care than is common in more developed countries.
The main purpose of integrating PET-CT into the staging algo-
rithm in our cohort was to identify patients who needed a change 
in the planned radiation fields or in treatment intent. Nearly half of 
our patients were allocated to palliative treatment, hypofraction-
ated radiotherapy, or extended field radiotherapy. In our previous 
cohort study, PET-CT findings imparted a 40% change in treatment 
intent.6 In the future, in our institution, affected nodal areas may 
receive intensity-modulated radiotherapy boosts; if so, the value 
and importance of including PET-CT in our staging algorithms will 
increase. A randomized Canadian trial comparing imaging with CT 
to that with PET-CT was performed to determine whether PET-CT 
would find more distant disease than CT, and whether or not patients 
would receive more extensive EBRT due to increased detection of 
para-aortic nodes.16 The two groups proved not to differ in terms of 
distant disease, but only eight out of 171 patients had such disease. 
More patients in the PET-CT group than in the CT group received 
extended field EBRT; some of the patients did not have positive 
para-aortic nodes and were treated off protocol.
The limitations of our study include the factors that influenced 
patient selection in the first 2 years of the cohort. In those years, 
we formed the cohort as a selected population of advanced disease 
patients who were deemed suitable for radical treatment and referred 
from the multi-disciplinary clinic. That sample is not representative of 
the entire cohort of cervical cancer patients at our institution. Due to 
limited surgical and diagnostic radiology resources, we were unable 
to biopsy equivocal pelvic or para-aortic nodes. The differential diag-
noses of nodal uptake in this population would include HIV-reactive 
adenopathy, and infectious processes, including local tumor infec-
tion and tuberculosis. Diagnosis relies on pattern recognition; our 
nuclear medicine physicians have extensive experience in reporting 
PET-CT findings in patients with tuberculosis, an endemic disease in 
the hospital’s catchment area. A number of patients had evidence of 
post-inflammatory lung lesions that may have represented metastatic 
disease in a small number of patients. Although the differences in age 
of our two study groups was significant, the evidence for an age effect 
(in the reported age ranges of our samples) on the prevalence of either 
metastases or reactive lymphadenopathy is lacking, and we did not 
consider it to be a limitation.
The strengths of our study include its sample size; our cohort of 
278 patients, of whom 84 were HIV-positive, is one of the largest 
in which HIV status and PET-CT findings have been described in 
any malignancy. Furthermore, consecutive patients were included; 
all patients referred in the study time period were evaluated. A 
multi-disciplinary team consisting of gynecological oncologists, 
a clinical oncologist, radiologists, and nuclear medicine physi-
cians contributed to the treatment decisions and clinical care in 
our setting. Imaging findings were discussed when needed and a 
collective decision was made on interpreting equivocal findings. A 
single oncology team was responsible for all final treatment deci-
sions providing consistent management for this patient cohort.
ConClusIon
We found no differences between HIV-positive and HIV-negative 
patients in nodal involvement or occult metastases, and PET-CT did 
not lead to, or justify, treatment differences between the groups. 
We will continue to follow this cohort for survival outcomes, and 
correlation of upstaging with outcome.
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Chapter 6 
 
Conclusions 
 
The primary overarching objective of these four cohort studies was to evaluate the impact 
of HIV infection on outcomes in locally advanced cervical carcinoma in a South African 
patient population. 
6.1 Summary of literature to date 
Prior to the commencement of this study very little available data was published in 
relation to the management of HIV-positive patients with radiotherapy. From 2012-2019 
outcomes were reported in cohort studies from Botswana, Brazil, Ethiopia, South Africa 
and the United States as detailed in Chapter 4.  
Additional publications include a systematic review by Ntekim et al from 20151. The 
authors found only 8 suitable studies – 5 retrospective and 3 prospective. Chapter 2 from 
this PhD was included in the review and was the only one assessed as having low bias in 
study methods and data analysis in the retrospective group. Additional studies included in 
this review were the cohorts from Kenya and India as discussed and two unpublished 
student dissertations from Johannesburg, South Africa. The overall conclusions of the 
review included mild increased toxicity in the HIV positive patients and higher adherence 
to completion of radiotherapy in those who commenced anti-retroviral therapy early.  
A study from the United States looking at those who did, or did not, receive treatment 
amongst HIV positive patients examined a cohort of cervical cancer patients and found 
that 11.7% (n=196) of HIV positive patients did not receive treatment compared to 3.7% 
(3.7%) in the HIV negative group [OR 2.81 (CI 1.77-4.45)]2. This re-iterates the 
challenges of access to care in this vulnerable group of women.  
More recently Einstein et al from the AIDS Malignancy Consortium published the 
outcomes of  Phase II study which enrolled HIV positive women with locally advanced 
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cervical cancer Stage IB2-IVA to receive standard of care chemoradiation3. Of the 38 
women treated - 31 completed prescribed therapy. The treatment had comparable 
tolerability to published outcomes in the HIV negative population and 76.3% one year 
PFS.  
The updated NCCN guidelines of cancer patients living with HIV suggest that cervical 
cancer patients should be treated as per routine SOC with the additional care of an HIV 
specialist and HIV pharmacists to evaluate drug-drug interactions4.  
With the update of the FIGO staging of cervical cancer in 2018 the need for accurate 
staging is now essential5. The use of PET-CT as a staging tool in HIV positive cervical 
cancer patients is rarely reported in the literature as described in Chapter 5. Since 
publication no new data is available.  
Overall the number of studies published on advanced imaging and radiotherapy 
management of HIV positive women with cervical cancer remains limited to date, all of 
these are restricted to cohort studies. 
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6.3 Summary of findings 
 
 
“Completion of and Early Response to Chemoradiation Among Human 
Immunodeficiency Virus (HIV)-Positive and HIV-Negative Patients With Locally Advanced 
Cervical Carcinoma in South Africa” was the first publication to report early outcomes for 
HIV-infected and uninfected patients treated with advanced 3-D conformal 
chemoradiation for cervical carcinoma in an LMIC. It was the largest cohort study of 
cervical carcinoma patients with and without HIV published. Adherence to treatment was 
high as the patients received managed oncology care in a multi-disciplinary setting with 
adequate resources and the sample included only patients deemed fit for therapy. The 
conclusions emphasised the importance of completion of radiotherapy, and in particular 
brachytherapy, to ensure good clinical outcomes among both HIV-positive and -negative 
patients with cervical carcinoma. 
 
“HIV Status and Acute Hematologic Toxicity Among Patients With Cervix Cancer 
Undergoing Radical Chemoradiation” examined the question of potential increased 
toxicity of oncological therapy in the vulnerable HIV-positive population. It was one of 
the largest cohort studies to compare HIV-positive and -negative patients from a 
single cohort with respect to treatment toxicity. It demonstrated that HIV-infected 
patients experienced more toxicities related to their scheduled chemotherapy than 
uninfected patients. Haematological toxicity appeared to be the most significant 
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toxicity; gastro-intestinal toxicity (GIT) was limited due to the use of advanced 3-D 
radiotherapy techniques. Previous published work showing increases in GIT toxicity 
was not confirmed in this cohort. The findings of increased haematological toxicity 
were not unexpected considering the additional effects of immunosuppression and 
concurrent antiretroviral therapy. 
 
“Five-year overall survival following chemoradiation among HIV-positive and HIV- 
negative patients with locally advanced cervical carcinoma in a South African cohort” was 
the first publication demonstrating long-term outcomes in HIV-positive cervical carcinoma. 
Outcomes among HIV-positive cervical carcinoma patients had previously been reported 
only for small cohorts (< 40 patients) living in low-income countries and treated with 2-D 
radiotherapy techniques. This study examined survival among patients with and without 
HIV treated with advanced techniques. In our large cohort, HIV-positive patients had 
poorer survival than HIV-negative patients; however, nearly 40% survived 5 years. The 
results inform practice for the radiation oncology community; in both HICs and LMICs, 
HIV-positive patients should receive the best standard of care, just as HIV-negative 
patients should. 
 
 
“HIV status does not impact PET-CT findings or radiotherapy treatment recommendation 
in patients with locally advanced cervical cancer” was one of the first studies to evaluate 
the role of PET-CT in the staging of cervical carcinoma in HIV-positive women, it is the 
largest cohort published to date. Notably, a high percentage these patients proved to 
have nodal involvement. This study revealed no difference in the findings on PET-CT 
between HIV-negative and HIV-positive patients with cervical carcinoma. In addition, 
subsequent treatment decisions, although influenced by the PET-CT results, were not 
associated with HIV status. 
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6.4 Summary of contributions 
 
Overall these studies aimed to answer questions regarding the effect of concurrent HIV 
infection and locally advanced cervical carcinoma. The common outcome is that HIV 
infection should not hinder the use of advanced imaging techniques or the best standard 
of care with chemoradiation. Patients must be established on cART, and support from 
infectious disease colleagues is essential to ensure that patients have a suppressed viral 
load and are compliant on therapy. Thereafter, the use of PET-CT for accurate staging is 
suitable for this population of patients and necessary to ensure that the treatment plan is 
correct. During treatment, due efforts must be made to maintain compliance on cART, 
prophylaxis with appropriate antibiotic cover, and pro-active management of 
haematological toxicities. Survival outcomes, although poorer in HIV-positive than HIV- 
negative patients, confirm that all patients with locally advanced cervical carcinoma 
should have equal access to appropriate oncological therapy. 
 
6.5 Future Research 
 
The questions that remain unanswered are many. The overall survival among HIV- 
positive patients was poorer than among those who were HIV-negative. The possible 
reasons include: HIV-related illness; potential interplay in toxicity of chemotherapy and 
cART preventing completion of adequate therapy; persistence of high-risk HPV leading to 
early recurrence. Future work will include investigation of drug-drug interactions between 
Cisplatin and cART; and testing for persistent HPV. Although no difference was 
demonstrated in PET-CT findings between the cohorts, many patients had nodal lesions 
that were not confirmed via cytology or histology; hence, the false positive rate in this 
population is unconfirmed. The outcomes in terms of recurrence and survival for the 
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patients with PET-positive nodal disease also need to be confirmed. Long-term follow-up 
of the nearly 300 patients who underwent PET-CT scanning will be undertaken. 
This body of work has established that women with locally advanced cervical cancer and 
HIV infection should be treated with the best standard of care. The many patients who 
participated in these cohort studies have helped to ensure that future patients with and 
without HIV will have equal access to health care resources in oncology in our institution. 
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